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Protein-Protein Interactions and Muscle cell Signaling Via Syntrophin
Abstract
Absence of dystrophin results in Duchenne muscular dystrophy (DMD), a lethal neuromuscular d isorder
that afflicts 1 in 3500 live male births. In the sarcolemma, dystrophin is associated with a complex of
proteins and glycoproteins, known as the dystrophin glycoprotein complex. The DGC constituents are
dystrophin, a-dys troglycan, b-dystroglycan, syntrophin, a-sarcoglycan, b-sarcoglycan, g-sarcoglycan, dsarcoglycan, and sarcospan. Not al l of these are single protein species. The syntrophins consists of a
group of three homologous proteins composed of acidic (a) and basic (b) components. Syntrophins are
known to self-associate to form oligomers.
In this dissertation, syntrophin's oligomerization and its interactions with the cell signaling components in
vitro in skeletal muscle were investigated.
Mouse a1-syntrophin sequences, produced as chimeric fusion proteins in bacteria, als o oligomerize and
in a micromolar Ca2+-dependent manner. Oligomerization was localized to the N-terminal pleckstrin
homology domain (PH1) or adjacent sequences; the second, C-terminal PH2 domain did not show
oligomerization. PH1 was found to se lf-associate and calmodulin or Ca2+ chelating agents such as EGTA
could effectively prevent this oligomerization. A single calmodulin bound per syntrophin to cause
inhibition of the precipitation. Calmodulin inhibited syntrophin oligomerization in the presence or absence
of Ca2+. Ca2+-binding to syntrophin is responsible for the inhibition by EGTA of syntrophin
oligomerization.
Syntrophins have been proposed to serve as adapter proteins. Blot overlay experiment s demonstrate that
a-, b-dystroglycan, and syntrophins all bind Grb2, the growth factor receptor bound adapter protein. Mouse
a1-syntrophin chimeric fusion proteins bind Grb2 in a Ca2+-independent manner. This binding was
localized to two proline rich sequences near the N terminal PH1 domain. This domain is interrupted by a
PDZ domain inserted nearly in middle of the PH1 domain dividing it into two parts: the N ter minal PH1
and C terminal PH1b subdomains. One proline rich sequence is Cterminal of PH1b while the other is
adjacent to and overlapping with the N terminal of PH1b. Grb2 contains two SH3 domains and both
contribute to binding. Intact, bacterial expressed Grb2 bound syntrophin with an apparent KD of 563 ± 15
nM. Grb2-C-SH3 domain bound syntrophin with slightly higher affinity than Grb2-N-SH3 domain. Crk-L, an
SH2/SH3 protein of similar domain structure but different specificity does not bind these s yntrophin
sequences.
Dystrophin glycoprotein complex has been proposed to be involved in signal transduction. We have
shown that laminin binding to a–dystroglycan causes syntrophin to recruit Rac1. Laminin-Sepha rose
precipitates Rac1, and to a lesser extent Rho-A and Ras, from the rabbit skeletal muscle membranes in a
pull-down assay. The presence of heparin, which inhibits the interaction between laminin and
a–dystroglycan preven ts recruitment of Rac1. A syntrophin antibody blocks recruitment of Rac1
suggesting that the signaling pathway requires syntrophin. Sos1 is also present in the recruited complex.
Jun N terminal kinase 2 is phosphorylated and activated only when laminin is attached to the dystrophin
glycoprotein complex. Thus, dystrophin glycoprotein complex recruits Rac1 via syntrophin through a
Grb2-Sos complex leading to activation of Jun N terminal kinase 2 only when it is attached to laminin. We
postulate this signals the muscle cell to grow.
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Abstract

Absence of dystrophin results in Duchenne muscular dystrophy (DMD), a lethal
neuromuscular disorder that afflicts 1 in 3500 live male births. In the sarcolemma,
dystrophin is associated with a complex of proteins and glycoproteins, known as the
dystrophin glycoprotein complex. The DGC constituents are dystrophin, α−dystroglycan,
β−dystroglycan, syntrophin, α−sarcoglycan, β−sarcoglycan, γ−sarcoglycan, δsarcoglycan, and sarcospan. Not all of these are single protein species. The syntrophins
consists of a group of three homologous proteins composed of acidic (α) and basic
(β) components. Syntrophins are known to self-associate to form oligomers.
In this dissertation, syntrophin’s oligomerization and its interactions with the cell
signaling components in vitro in skeletal muscle were investigated.
Mouse α1-syntrophin sequences, produced as chimeric fusion proteins in
bacteria, also oligomerize and in a micromolar Ca2+-dependent manner. Oligomerization
was localized to the N-terminal pleckstrin homology domain (PH1) or adjacent
sequences; the second, C-terminal PH2 domain did not show oligomerization. PH1 was
found to self-associate and calmodulin or Ca2+ chelating agents such as EGTA could
effectively prevent this oligomerization. A single calmodulin bound per syntrophin to
cause inhibition of the precipitation. Calmodulin inhibited syntrophin oligomerization in
the presence or absence of Ca2+. Ca2+-binding to syntrophin is responsible for the
inhibition by EGTA of syntrophin oligomerization.
Syntrophins have been proposed to serve as adapter proteins. Blot overlay
experiments demonstrate that α-, β-dystroglycan, and syntrophins all bind Grb2, the
v

growth factor receptor bound adapter protein. Mouse α1-syntrophin chimeric fusion
proteins bind Grb2 in a Ca2+-independent manner. This binding was localized to two
proline rich sequences near the N terminal PH1 domain. This domain is interrupted by a
PDZ domain inserted nearly in middle of the PH1 domain dividing it into two parts: the N
terminal PH1 and C terminal PH1b subdomains. One proline rich sequence is Cterminal of PH1b while the other is adjacent to and overlapping with the N terminal of
PH1b. Grb2 contains two SH3 domains and both contribute to binding. Intact, bacterial
expressed Grb2 bound syntrophin with an apparent KD of 563 ± 15 nM. Grb2-C-SH3
domain bound syntrophin with slightly higher affinity than Grb2-N-SH3 domain. Crk-L,
an SH2/SH3 protein of similar domain structure but different specificity does not bind
these syntrophin sequences.
Dystrophin glycoprotein complex has been proposed to be involved in signal
transduction. We have shown that laminin binding to α–dystroglycan causes syntrophin
to recruit Rac1. Laminin-Sepharose precipitates Rac1, and to a lesser extent Rho-A and
Ras, from the rabbit skeletal muscle membranes in a pull-down assay. The presence of
heparin, which inhibits the interaction between laminin and α–dystroglycan prevents
recruitment of Rac1. A syntrophin antibody blocks recruitment of Rac1 suggesting that
the signaling pathway requires syntrophin. Sos1 is also present in the recruited
complex. Jun N terminal kinase 2 is phosphorylated and activated only when laminin is
attached to the dystrophin glycoprotein complex. Thus, dystrophin glycoprotein complex
recruits Rac1 via syntrophin through a Grb2-Sos complex leading to activation of Jun N
terminal kinase 2 only when it is attached to laminin. We postulate this signals the
muscle cell to grow.
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Chapter 1. Introduction

This dissertation deals with the proteins involved in muscular dystrophies. In this
chapter, I will review briefly this group of diseases and the proteins, which are found to
be malfunctioning.

Muscular dystrophies
Different pathological conditions can afflict muscle. While myopathy refers to any
pathological change, a dystrophy is characterized by a progressive course with
continued regeneration and fibrosis. Regeneration serves to replenish the part of the
muscle, which dies. Fibrosis is an undesired side effect due to the activation of
connective tissue cells producing an interstitial type of extracellular matrix rich in
interstitial collagen. Many myopathies are caused by defects in the link between the
muscle cell interior and the surrounding basement membrane (1,2). In muscular
dystrophies a primary defect causes muscle necrosis, regeneration and a progressive
degeneration of the muscle tissue.
Muscular dystrophies are a group of almost 40 neuromuscular disorders. Various
muscular dystrophies that are caused by the defect in the basal lamina, dystrophin,
dystroglycans and sarcoglycans will be discussed in this section. Each defect gives rise
to a different phenotype. Since components of the dystrophin glycoprotein complex (see
below) are involved in Duchenne muscular dystrophy-like disorders, a number of related
neuromuscular diseases are now collectively called as dystrophinopathies (3,4).
1

Duchenne muscular dystrophy (DMD)
This is the most common of the different muscular dystrophies. Even as recently
as 15 years ago, the genetic basis of this disease was unknown. The fact that
essentially all of the patients were males showed that the disease is X-linked. Linkage
analysis of random cloned genomic DNA fragments and analysis of rare female DMD
patients eventually led to localization of the gene for this disorder to chromosome Xp21
(5). Further studies to purify dystrophin, showed that dystrophin is a cytoskeletal protein
closely associated with other peripheral and integral membrane proteins and
glycoproteins (6,7), the complex is now called the dystrophin glycoprotein complex. In
1986, the DMD gene was identified (8) and its complementary DNA (cDNA) was
sequenced within a year (9) and the DMD gene product, dystrophin, identified (10).
DMD is a compound lesion due to disruption of the dystrophin glycoprotein complex,
caused by the loss of dystrophin. The subsarcolemmal undercoat of DMD muscle is
deficient in dystrophin. DMD is a devastating neuromuscular disorder with an
occurrence of 1 in 3500 live male births (3,11). Progressive muscle weakness, elevated
serum creatine kinase activity, as well as an abnormal variation in muscle fiber
diameter, the presence of necrotic and regenerative muscle fibers and an increase of
endomysial fat and connective tissue is present before the age of 5 years (11). A loss of
unassisted ambulation usually occurs before the age of 13 years and progressive
weakening of the heart and other essential muscle groups lead to lethal cardiac or
respiratory failure (11). The two animal models mdx mouse and grmd dog are both
related to DMD (none produce dystrophin). Dystrophin deficient skeletal muscle
2

biopsied from patients affected with DMD exhibited 80 to 90% reduction in all
dystrophin-associated proteins.

Becker muscular dystrophy (BMD)
BMD is typically the milder of the two. In BMD, the dystrophin rod is shorter than
normal in most cases (resulting from internal deletions within the DMD gene) or longer
in others (resulting from duplication of the DMD gene). The shorter dystrophin has intact
actin-, dystroglycan- and syntrophin-binding domains. So even severely truncated (12)
or elongated dystrophins may connect the dystroglycan complex to the actin filaments.
In BMD muscle fibers, the dystrophin axis is present even though the amount of
dystrophin is decreased and utrophin, a dystrophin related protein, expression is
upregulated (13). Thus, the dystrophin-axis is reduced but still partially preserved. This
could be responsible for the milder symptoms of BMD as compared to DMD.

Dystrophin glycoprotein complex (DGC)
Dystrophin is a long, slender protein and is found almost exclusively in the cell
periphery on the cytoplasmic face of the sarcolemma in normal muscle (14), exhibits
properties typical for membrane cytoskeletal components (7,15,16). The 427 kDa form
of dystrophin is found in skeletal, cardiac, and smooth muscle tissue and is also present
in neurons and glia cells of the central nervous system. Confocal microscopy has shown
dystrophin to lie in an array of thick bands that localize at the sites of attachment of the
sarcomeres to the muscle plasma membrane (17,18). Dystrophin binds to F-actin at the
N-terminal region. The C-terminal domain of dystrophin binds DGC glycoproteins.
3

Dystrophin forms an intricate part of the muscle cytoskeleton and may function to link
the normal contractile apparatus to the sarcolemma. Following the discovery of
dystrophin (8,9), the protein missing in Duchenne muscular dystrophy, a number of
proteins forming a complex tightly associated with dystrophin (dystrophin associated
proteins, DAPs) has been revealed (6,19) in the digitonin solubilized sarcolemmal
fraction. Dystrophin along with its associated proteins and glycoproteins, also called the
DGC, is present in the skeletal and cardiac muscle sarcolemma at regular intervals. The
membrane organization of the DGC in the sarcolemma is shown in Figure 1.1. This
complex of proteins at the sarcolemma of skeletal and cardiac muscle is critical for the
integrity of the cell membrane (20). Dystrophin is associated with the 156 kDa
dystrophin associated glycoprotein (α-DG) by way of the 50 kDa (α-sarcoglycan), 43
kDa (β-dystroglycan), and 35 kDa (γ-sarcoglycan) transmembrane glycoprotein complex
and this suggests that the dystrophin serves as a special link between the actin
cytoskeleton and components external to the sarcolemmal membrane (20). This
complex can be subdivided into three subcomplexes according to their localization
namely, the dystroglycan complex, sacrcoglycan complex and a complex conatining
syntrophin, dystrophin and dystrobrevin.
The dystroglycan subcomplex consists of
α-dystroglycan (156 DAG)
β-dystroglycan (43 DAG)
These are translated from a single mRNA as a 97 kDa protein which is then
processed into two peptides (21) which are closely associated (22). They are
ubiquitously expressed in various tissues. The high mass is a result of extensive
4

Figure 1.1 The membrane organization of the dystrophin glycoprotein complex.
Dystrophin (Dys) is associated with α-dystroglycan (α-DG) by way of the 50 kDa (αSG), 43 kDa (β-DG), and 35 kDa (γ-SG) transmembrane glycoprotein complex. βSarcoglycan (β-SG), δ-sarcoglycan (δ-SG) and sarcospan are parts of the sarcoglycan
complex. Syn indiacates syntrophin while CTD stands for C-terminal domain, CRD for
cysteine rich domain and WW for WW domain of dystrophin.

5

glycosylation. The sarcoglycan subcomplex consists of four transmembrane
glycoproteins namely α−, β−, γ−, δ−sarcoglycan, and sarcospan. ε−Sarcoglycan is a fifth
sarcoglycan, which is highly homologous to α-sarcoglycan. α- and ε-sarcoglycan
however do not exist together in a complex. The sarcoglycan complex is expressed
specifically in skeletal and cardiac muscles (23,24).
A subsarcolemmal complex comprising:
Dystrophin (427 kDa)
Syntrophins (59 kDa)
Dystrobrevins (87 kDa)
Syntrophins and dystrobrevin are intracellular proteins that are associated with
the C-terminal domain of dystrophin.

The dystroglycan subcomplex interacts with the basal lamina
α-Dystroglycan, an extracellular protein, binds to laminin probably via its sugar
chains (25). This interaction is Ca2+ dependent (25) and heparin and Ca2+ chelators
such as ethylene diamine tetraacetic acid (EDTA) inhibit it (25). α-Dystroglycan seems
to be essential in cell surface matrix organization (26,27). α-Dystroglycan also binds to
β-dystroglycan (22). β-Dystroglycan, in turn binds to the cysteine-rich domain and the
first half of the C-terminal domain of dystrophin, which are collectively called the
dystroglycan-binding domain (D-domain). β-Dystroglycan appears to play a fundamental
role, among the DAPs, in connecting the intracellular cytoskeleton to the extracellular
basal lamina (28), a function that does not appear to be limited to the skeletal and
cardiac muscles. The dystroglycan knockout mice do not survive embryonic life (29).
6

Basal lamina is composed of a network including collagen fibers, laminin,
entactin, and heparan sulfate proteoglycans. The basal lamina covers each muscle fiber
in close contact with the sarcolemma forming a thick sheet and serves to protect the
muscle fibers from mechanical damage. Laminin-2, the muscle specific isoform of
laminin which is also called as merosin, when missing leads to severe form of
congenital muscular dystrophy (30) or the milder dystrophy of the dy/dy mice (31).
However merosin is also present in peripheral nervous system and brain. It also binds
α7β1 integrin at the sarcolemma of skeletal muscle (27) and mutations of the α7 subunit
also causes muscular dystrophy (32). Congenital muscular dystrophy (CMD) is a
collective name of muscular dystrophies probably due to defects in various genes.
Merosin negative muscular dystrophy is caused by the absence of the α2 subunit of
laminin also called merosin. There is an increased expression of the α1 subunit of
laminin in skeletal muscle basal lamina (33). Defects of dystrophin, the dystroglycan
complex and the sarcoglycan complex are not present. However, because of absence
of laminin the mechanical link between the extracellular matrix and the cytoskeleton
may be interrupted leading to weakening of the muscle and the DGC may not be fully
functional. The defect of merosin is primarily responsible for the muscle necrosis
observed.

The sarcoglycan subcomplex
Sarcoglycans are associated with the DAPs by a lateral association with the
dystroglycan complex. Except for β− and ε−sarcoglycan, all sarcoglycans are
specifically expressed in striated muscles. Sarcoglycans can be copurified as a
7

subcomplex, however, only β-, γ-, and δ- sarcoglycans can be chemically cross-linked to
each other (22,34). All five sarcoglycans have cysteine residues in the extracellular
domain, although, only β-, γ-, and δ- sarcoglycans appear to form disulfide bonds (34).
The extracellular portion of sarcoglycans has been shown to interact with the
dystroglycans and each other in in vitro experiments (22). Recent investigations have
shown that the association between β-, and δ- sarcoglycans, and, to a lesser extent, γsarcoglycan is very strong. Among the sarcoglycan complex, α-sarcoglycan appears to
be loosely associated with the other components. From these observations, the authors
concluded that β-, γ-, and δ- sarcoglycans form a distinct subcomplex, whereas αsarcoglycan appears to function as a separate unit (34).
Except for ε−sarcoglycan, deficiencies of other sarcoglycans have been
implicated in etiology of several of the limb girdle muscular dystrophies (35). Severe
childhood autosomal recessive muscular dystrophy (SCARMD) is pathologically and
symptomatically very similar to that of DMD (36). Originally, it was defined as
α−sarcoglycan deficiency (37), in which dystrophin and the dystroglycan complex are
present at normal levels. However, it was later found that this is not a genetically
homogeneous disease, but a group of muscular dystrophies with similar phenotypes
caused by damage to different genes (38). Thus, in SCARMD, all components of the
sarcoglycan complex are absent. The hamster with autosomal recessive muscular
dystrophy has been reported to have defect of the entire sarcoglycan complex and is
considered an animal model of SCARMD (39). However, the phenotypes of SCARMD
and hamster dystrophy are different. In addition, skeletal muscle is involved
predominantly in SCARMD while in hamster dystrophy cardiac muscle is predominantly
8

involved.
Sarcospan is the most recently characterized component of the DAPs (40). It is a
member of a tetraspan super family of proteins, which are known to mediate
transmembrane protein interactions. It also interacts with sarcoglycans driving their
assembly to the sarcolemma and thereby stabilizing the complex (40).

Syntrophin
The 58 kDa cytoplasmic peripheral membrane protein was originally identified in
the Torpedo electric organ, and shown to localize to the post synaptic neuromuscular
junction in mammals (41). This 58 kDa component is called syntrophin (syntrophos from
Greek, meaning companion). Syntrophin also copurifies with dystrophin. Syntrophins
associated with dystrophin from rabbit skeletal muscle are biochemically heterogeneous
group of three 58 kDa intracellular membrane associated proteins. Syntrophins appear
as a triplet by one dimensional SDS-PAGE while when separated by two-dimensional
electrophoresis it appears as two clusters of 58 kDa proteins with different isoelectric
points (pI), one which is slightly acidic (α, pI=6.4) and the other which is quite basic (β,
pI=9) (42). Human acidic α1-syntrophin and the basic β2 syntrophin have been cloned
and characterized (43). The deduced amino acid sequence of the three syntrophins
namely α1, β1, and β2 show overall sequence similarity (α1-syntrophin sequence is 54
and 50% identical to β1 and β2 syntrophin) and that they are nearly identical to their
homologues in mouse, suggesting a strong functional conservation among the
individual isoforms. Human α1-syntrophin is most predominantly expressed in striated
muscles and in brain while the β syntrophins are more ubiquitously expressed (43,44).
9

Syntrophin binding to the DGC components
α−Syntrophin has been shown to bind to all three syntrophins (45,46),
α−sarcoglycan (46,47), and γ−sarcoglycan (46). Syntrophin also has been shown to
bind dystrophin (48) and this is discussed later.

Domain structure of syntrophin
All syntrophins contain two pleckstrin homology domains (PH domain), an Nterminal PH1 domain and a PH2 domain. This domain structure is shown in Figure 1.2.
The PH1 domain is interrupted by a PDZ domain, a homologous domain found in post
synaptic density 95 kDa protein, neuronal nitric oxide synthetase, and other membrane
proteins. The PDZ domain was named for the first three proteins in which this ~90
amino acid motif was identified: the Postsynaptic density protein (PSD-95), the
Drosophila disks-large protein (Dlg), and the Zona Occludens 1 (ZO-1) protein.
Syntrophins also have a unique domain at the C-terminus, called the SU domain.
Different interactions of syntrophin with other proteins have been localized and are
discussed below.

PH domain
Pleckstrin homology domains derive their name from pleckstrin, the major protein
kinase C substrate of platelets. PH domains are a family of compact protein modules
defined by a sequence of roughly 100 amino acids. Many enzymes, which have
important regulatory functions, contain PH domains, and the mutant forms of several
10

Figure 1.2 Domain structure of syntrophin.
Numbers in the parentheses represent the syntrophin amino acid sequences present in
each fusion protein.
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such proteins are implicated in oncogenesis and developmental disorders. PH domains
frequently possess two biological activities: they bind phosphatidylinositol 4,5bisphosphate and the heterotrimeric GTPase protein βγ subunits (49-51). The PH
domain of α1-syntrophin binds phosphatidylinositol 4,5-bisphosphate (PtdIns4,5P2) (52).
The half-maximal binding occurred at 1.9 µM PtdIns4,5P2. The binding is specific for
PtdIns4,5P2 and does not occur with six other tested lipids including the similar
phosphatidylinositol-4-phosphate. The binding is localized to the N terminal PH1
domain; the second C-terminal PH2 domain does not bind lipids. Key residues in
PtdIns4,5P2 binding to a PH domain are conserved in α−syntrophin’s PH1 domain and
absent in PH2 domains (52).
Syntrophins also bind calmodulin (53). This binding has been localized to two
sites, one at the N-terminal region of the PH1 domain and the other at the N-terminal of
the PDZ domain (54). Whether this N-terminal calmodulin binding is Ca2+ dependent
(54) or independent (48) is controversial (55).
Syntrophin has also been shown to bind Ca2+ (48) at two sites residing in the
amino-terminal 274 residues, and Ca2+ binding affects calmodulin binding at high
concentrations of syntrophin (48).

PDZ domain
PDZ domains are known to play a role in protein-protein interactions.
Syntrophin's PDZ domain has been shown to bind neuronal nitric oxide synthetase (56).
Neuronal nitric oxide synthetase (nNOS) is concentrated at synaptic junctions in brain
and at motor endplates in skeletal muscle. nNOS contains a PDZ motif of ~100 amino
12

acids and mediates association with syntrophin through the PDZ domains on each
protein (57,58). nNOS and α1-syntrophin share similar distribution in skeletal muscle
fast fibers (56). Thus syntrophin acts as a modular adapter protein linking a signaling
enzyme, nNOS, to the sarcolemmal dystrophin complex.
Stress activated protein kinase-3 (SAPK3), a member of mitogen activated
protein kinase family is abundantly expressed in skeletal muscles (59). It also binds
through its C-terminal sequence –KETXL to the PDZ domain of α1-syntrophin (59).
SAPK3 phosphorylates α1-syntrophin at Serine residues 193 and 201 in vitro. SAPK3
and α1-syntrophin colocalize at the neuromuscular junction in skeletal muscle.
Sodium channels SkM1 and SkM2 from extracts of skeletal and cardiac muscle,
respectively, copurify with syntrophin and dystrophin. Peptides corresponding to the Cterminal 10 amino acids of SkM1 and SkM2 are sufficient to bind detergent-solubilized
muscle syntrophins and inhibit the binding of native sodium channels to syntrophin PDZ
domain fusion proteins. They bind specifically to PDZ domains from α1-, β1-, and β2syntrophin. These peptides also inhibit binding of the syntrophin PDZ domain to the
PDZ domain of neuronal nitric oxide synthase, an interaction that is not mediated by Cterminal sequences. Brain sodium channels, which lack the (S/T)XV consensus
sequence, also copurify with syntrophin and dystrophin, an interaction that does not
appear to be mediated by the PDZ domain of syntrophin. Thus, syntrophins link sodium
channels to the actin cytoskeleton and the extracellular matrix via dystrophin and the
DAPs (60).
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SU domain
A domain unique to syntrophins, the SU domain has been shown to bind Ca2+calmodulin with an apparent affinity of 18 nM (48) and the SU domain, in addition to
other sequences in the C-terminal of the protein, binds to dystrophin. This binding does
not require Ca2+. Ca2+-calmodulin binding inhibits the syntrophin-dystrophin interaction
(48).

Function of the DGC
Progress in identifying and characterizing DGC proteins was accompanied by
investigations on their role in maintaining muscle cell integrity. Studies on isolated DGC
have shown that α−dystroglycan is an extracellular, matrix binding-protein (20) and is
attached to the transmembrane proteins of the DGC. Later it was also shown that
α−dystroglycan showed direct binding to the extracellular matrix protein, laminin (61).
This binding was Ca2+ dependent and the entire DGC could be purified by using
laminin-Sepharose affinity chromatography (25). Homology studies showed that
dystrophin’s N terminal domain bears a strong resemblance to the actin-binding domain
of chicken α−actinin (62). The binding of actin by dystrophin and the interaction of
α−dystroglycan with laminin led to the hypothesis that one of the DGC functions is to
link the extracellular matrix to the actin cytoskeleton (25). A loss of dystrophin and the
accompanying loss of other DGC proteins, such as α−dystroglycan (19) would result in
a loss of this link, making the tissue susceptible to degradation. Disruption of this link
has been proposed to cause DMD/BMD and SCARMD (63).
14

Signal transduction
The DGC is important in maintaining muscle cell integrity. Madhavan, et al.
originally proposed in 1992 that the DGC was a signal transduction complex (53). Ca2+ calmodulin binding and phosphorylation-dephosphorylation have been shown to operate
on DGC proteins, and suggest that these signal transduction mechanisms may be
important to the etiology of muscular dystrophies.
Dystrophic tissue has been shown to have increased levels of Ca2+ and
calmodulin, the major intracellular mediator of Ca2+ signal in eukaryotes (64). The
increased Ca2+ concentration was suggested to be responsible for increased muscle
protein degradation by increased Ca2+ activated proteases (65).
Protein phosphorylation-dephosphorylation is an important form of signal
transduction that occurs in all cells (66). Dystrophin is phosphorylated by an
endogenous protein kinase (67). DGC is also phosphorylated in vivo (68,69) and in
sarcolemmal preparations (70). A protein phosphatase has also been shown to
dephosphorylate dystrophin (67) and is probably calcineurin, the type 2b protein
phosphatase (71).
Indeed, the numerous signal transduction proteins now known to have
association with the DGC makes it almost certain that this complex is involved
somehow in cell signaling. Binding of syntrophin to nNOS (56), SAPK3 (59), muscle and
nerve voltage gated Na+ channels (60) may participate in signal transduction
mechanisms. Grb2 has also been shown to recruit focal adhesion kinase, FAK125, to the
DGC (72,73). Phosphorylated tyrosines on FAK125 act as docking sites for molecules
15

such as Grb2 that participate in multiple signal transduction pathways.
Various other types of muscular dystrophies such as Fukuyama type muscular
dystrophy, Emery-Dreifuss muscular dystrophy along with congenital muscular
dystrophy (CMD), severe childhood autosomal recessive muscular dystrophy, and limb
girdle muscular dystrophy have been discussed in detail by Bertorini et al. (4).

Summary
In this dissertation, different in vitro interactions of syntrophin are studied.
Oligomerization of syntrophin has been characterized and discussed in Chapter 2.
Syntrophin binding to Grb2 has been identified, characterized and discussed in Chapter
3. Chapter 4 describes the signal transduction pathway going via syntrophin when the
DGC is attached to laminin leading to phosphorylation and activation of the Jun N
terminal kinase 2. Several discoveries were made during the course of these studies
that contribute towards a more complete characterization of the DGC. An understanding
of the DGC function is required in order to effectively develop treatments for patients
afflicted with muscular dystrophy.
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Chapter 2. The Oligomerization Of Mouse α 1-Syntrophin And SelfAssociation Of Its Pleckstrin Homology Domain 1 Containing
Sequencesi

Introduction
Syntrophin, a peripheral membrane protein, was first identified in the
postsynaptic membrane of Torpedo (74). Syntrophins were found to be associated with
the dystrophin glycoprotein complex (75) whose defects cause Duchenne, Becker,
various limb girdle, and other muscular dystrophies (30). Syntrophins are a multigene
family of homologous proteins, namely α1, β1 and β2. α1-Syntrophin is predominantly
expressed in striated muscles and brain, whereas β syntrophins are ubiquitous in
mammalian tissues (43). All syntrophins are known to contain two pleckstrin homology
(PH) domains, an N-terminal PH1 domain and a PH2 domain. This domain structure is
shown diagrammatically in Figure 2.1. The PH1 domain is interrupted by an inserted
PDZ domain, a homologous domain found in the postsynaptic density 95 kDa protein,
neuronal nitric oxide synthetase, and other membrane proteins (57,58). Syntrophins
also have a unique domain at the C-terminus, the syntrophin unique (SU) domain.
Recently, the PH1 domain of α1-syntrophin has been reported to bindii

i

Reproduced with permission from Biochemistry, Oak, S. A., and Jarrett, H. W. (2000)

39(30), 8870-7. Copyright [2000] American Chemical Society.
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Figure 2.1 Diagrammatic representation of fusion proteins containing α1-syntrophin
sequences.
The shaded portion shows the location of PH1 domain. Numbers in the parentheses
represent the syntrophin amino acid sequences present in each fusion protein.
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phosphatidylinositol 4,5-bisphosphate (Ptdlns4,5P2) (52). Syntrophins also bind
calmodulin (53). The SU domain of syntrophin has also been shown to bind Ca2+calmodulin (48), a ubiquitous calcium binding protein. The N-terminal of the PH1
domain and the N-terminal of the PDZ domain have been reported (54) to also bind
calmodulin. Whether this N-terminal calmodulin binding is Ca2+-dependent (54) or independent (48) is controversial (55). α1-Syntrophin has also been shown to bind
calcium (48). Thus, Ca2+, calmodulin, and Ptdlns4,5P2 may affect the activities of
syntrophins. Syntrophins may also play a role as an adapter that links different cellular
proteins to the dystrophin glycoprotein complex (76). PH domains are also known to
bind heterotrimeric G protein, Gβγ and syntrophin’s PDZ domain binds voltage gated
Na+-channels in muscles and nerves (60) and the MAP kinase, SAPK3 (59). The SU
domain binds Ca2+-calmodulin and the SU domain plus other sequences in the Cterminal of the protein bind to dystrophin, the protein product of the Duchenne muscular
dystrophy gene. Ca2+-calmodulin binding inhibits the syntrophin-dystrophin interaction
(48). α1-Syntrophins are known to self-associate and associate with other syntrophins
(43,45,46,48). This oligomerization is currently only poorly characterized.
Oligomerization of syntrophins is also likely to be physiologically relevant since the
dystrophin glycoprotein complex contains one copy of most constituents but two
syntrophins, suggesting self-association to at least a dimer in vivo (20). In this part of
the dissertation, we have studied oligomerization of the mouse α1-syntrophin. We show
here that the PH1 domain of α1-syntrophin is involved in the oligomerization of
syntrophin in vitro and that Ca2+ regulates it.
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Experimental procedures

Materials
Endoproteinase Xa (from bovine plasma) was from New England Biolabs. T7
monoclonal antibody for [His]6-Tag fusion proteins was from Novagen. Goat anti-rabbit
IgG (H+L)-alkaline phosphatase conjugate and goat anti-mouse IgG (H+L)-alkaline
phosphatase conjugate were from BioRad. Ni2+-NTA-agarose was from Qiagen.
Cyanogen bromide pre-activated Sepharose was from Sigma. All other chemicals were
of the highest purity available commercially.

Fusion proteins
The syntrophin fusion proteins [His]6-Syn, [His]6-Syn A, maltose binding protein
(MBP) fusions MBP-Syn B, and MBP-Syn H were prepared as described previously
(48). pET32 plasmid constructs for PH1, PH2, and the PDZ domain were the generous
gift from Drs. Steven Gee and Stan Froehner, (Department of Physiology, University of
North Carolina, Chapel Hill). pET32 plasmids encoding [His]6-thioredoxin-PH1, -PH2,
and -PDZ were used to express proteins referred to here as: [His]6-PH1, -PH2, and –
PDZ (60). The His-Tag fusion proteins were purified by using Ni2+-NTA-agarose from
Qiagen as described earlier (48). The MBP fusion proteins were purified using amylose
affinity chromatography as described previously (77). The purity of the proteins was
determined by 12% SDS-polyacrylamide gel electrophoresis using the method of
Laemmli (78). The major bands of the fusion proteins were of expected size and
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relatively high purity. The Bradford assay (79) was used to determine the protein
concentrations with bovine serum albumin as the standard.

Ultracentrifuge oligomerization assay
All proteins were centrifuged at 100,000 rpm (BeckmanTLA-100 rotor) before
dialysis in order to remove any insoluble protein. 50 µl of fusion protein was dialyzed in
buffer A (50 mM Tris, pH 7.5, 100 mM KCl) containing 100 µM Ca2+ or 100 µM EGTA
overnight at 40. The next day 10 µl of the dialyzed sample was saved as the total 'T'. To
this 10 µl of 2X Laemmli buffer was added. 20 µl of the remaining sample was subjected
to centrifugation at 100,000 rpm (Beckman TL-100 Ultracentrifuge, TLA - 100 rotor,
440,000 gmax) for 15 min at 40 in polycarbonate tubes (7 x 20 mm; Beckman). Then 10 µ
l of the supernatant (S) was taken and 10 µl of 2X Laemmli buffer (1X is 62.5 mM
Tris/HCl, pH 6.8, 0.001% bromophenol blue, 6.25% glycerol, 2% sodium dodecylsulfate,
and 0.7 M 2-mercaptoehanol) was added to it. After removing the remaining
supernatant, the pellet (P) was dissolved in 40 µl of 1X Laemmli buffer with vigorous
vortexing and using a bath type sonicator. The samples were heated for 5 min at 950,
applied to a 12% SDS-PAGE gel (78), and stained with Coomassie brilliant blue. The
amount of protein in the total, supernatant and pellet was compared using Alpha
Innotech Camera System (The Alpha Innotech Corp.) and AlphaImager 2000 3.3b
software. The amount of the protein in ‘T’ was treated as 100% and the percentage of
the protein in ’S’ and ‘P’ was calculated accordingly.
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Solid phase binding assays
1.6 mg of Syn (0.8 mg/ml) and 1.8 mg of PH1 (1.5 mg/ml) were coupled to 1 g of
cyanogen bromide-activated Sepharose (Sigma) using procedures recommended by
the manufacturer (Pharmacia). The support was then washed with the coupling buffer
(0.1 M NaHCO3, pH 8.3, 0.5 M NaCl) and blocked for 2 hours with 0.1 M Tris-HCl, pH 8,
0.5 M NaCl. The amount of the protein coupled (0.2 mg/g of Sepharose for syntrophin
and 1.67 mg/g of Sepharose for PH1) was determined by the difference in the ultraviolet
absorption of the added protein and that recovered from coupling in the wash fractions.
For negative controls, CNBr-activated Sepharose to which no protein was coupled was
used.
200 µl of a 50% slurry of Syn-Sepharose containing 3 µg Syn was equilibrated
with buffer A containing 100 µM Ca2+ and then incubated with different fusion proteins
(25 µg) for 1 hour at room temperature and for 30 minutes on ice with gentle mixing in a
final volume of 200 µl. For control, Sepharose without any protein coupled to it was
used. After the incubation, Syn-Sepharose was washed three times with 0.5 ml of
BSA/TTBS (1 mg/ml BSA in 20 mM Tris-HCl, pH 7.5, 0.5 M NaCl and 0.05%Tween-20).
The protein was eluted using 60 µl of 2x Laemmli buffer. Samples were heated for 5 min
at 950. The samples were then centrifuged for 5 min at room temperature to remove the
resin, applied to electrophoresis on a 12% SDS-PAGE gel (78), and electroblotted onto
nitrocellulose paper (80). The paper was then blocked with 10 mg/ml BSA in TTBS.
After washing extensively with 1 mg/ml BSA/TTBS, the blot was incubated with affinity
purified anti-MBP (1:1000 dilution) for MBP fusion proteins or T7 monoclonal antibody
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(Novagen, 1:10,000 dilution) for His-Tag fusion proteins. Goat anti-rabbit IgG (H+L)alkaline phosphatase conjugate and goat anti-mouse IgG (H+L)-alkaline phosphatase
conjugate (both 1:1000 dilution, BioRad) were used, respectively, following the primary
antibodies. The blot was developed using 1:100 dilution each of 30 mg/ml NBT (in 70%
dimethylformamide) and 15 mg/ml BCIP (in 100% dimethylformamide) in buffer AP
(0.1M NaHCO3, 1mM MgCl2, pH 9.8). A similar experiment was carried out using PH1Sepharose.

His tag digestion
50 µl of the Syn A was digested with 1 µl of endoproteinase Xa (1 mg/ml) by
dialyzing for 12 hours at 40 in digestion buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 2 mM
CaCl2 and 1 mM NaN3). Cleavage of the fused sequences was confirmed on 12% SDSPAGE. The ultracentrifugation experiment was performed using the digested protein
and compared with the undigested protein.

Size exclusion chromatography
Syn A (0.8 mg/ml) was dialyzed in MC (10 mM Mops, pH 7.0, 90 mM KCl, 1 mM
CaCl2) or ME buffer (10 mM Mops, pH 7.0, 90 mM KCl, 1 mM EGTA) for 12 hr at 40.
300 µl of the dialyzed protein was loaded on a Sepharose 4B column (1.4 cm x 42.5
cm). 80 ml of mobile phase (MC or ME buffer) was passed through the column at a flow
rate of 0.33 ml/min and 1.5 ml fractions were collected. Three equivalents of calmodulin
were added to Syn A in the experiments involving calmodulin. A microtiter plate
(Dynatech Immulon 1) was coated by incubation of 100 µl/well of each fraction for 4 hr
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at 40. The plate was then blocked by replacing the fractions with 300 µl/well of 30 mg/ml
BSA in AC7.5 buffer (50 mM Tris-Cl, pH 7.5, 100 mM KCl, 3 mM MgCl2, 1 mM CaCl2).
All subsequent operations were at room temperature and 100 µl/well. After washing
extensively with AC7.5T/BSA (buffer AC7.5, 0.1 % Tween-20, 1 mg/ml BSA), the plate
was incubated with T7 monoclonal antibody (Novagen, 1:10,000 dilution). Goat antimouse IgG (H+L)-alkaline phosphatase conjugate (both 1:1000 dilution, BioRad) was
used following the primary antibody. The plate was then washed once with 1 mg/ml
AC7.5T/BSA followed by two immediate washes of diethanolamine buffer (10 mM
diethanolamine, 0.5 mM MgCl2). The plate was then developed by incubation with 100 µ
l/well of 1 mg/ml p-nitrophenylphosphate in diethanolamine buffer. The absorption at
405 nm was determined.

Results
Mouse α1-syntrophin sequences expressed as fusion proteins are
diagrammatically represented in Figure 2.1. The regions of mouse α1-syntrophin’s
amino acid sequence in each construct are given in parenthesis. The boundaries of the
PH1 domain are not well defined. Our PH1 construct contains some additional
sequences as shown in Figure 2.1. PH1 domain sequences are shaded in the fusion
proteins containing them as these are involved in oligomerization (see below). Syn, Syn
A, PH1, PH2 and PDZ were produced as His-Tag fusion proteins while Syn B and Syn
H were produced as maltose binding fusion proteins. Each fusion protein was
expressed and affinity purified using Ni2+-NTA-agarose for His-Tag fusion proteins and
amylose-agarose for maltose binding fusion proteins.
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Figure 2.2 shows the purity of the proteins used for the experiments. The purified
proteins are mostly full length but some show partial proteolysis. This partial proteolysis
has been investigated and discussed previously (48,77). All the proteins were boiled for
5 min in the presence of SDS and 2-mercaptoethanol. This was necessary to observe
predominantly the monomer molecular weight of PDZ domain protein which otherwise
migrates as a dimer (52). The experiments were repeated with different preparations of
each protein and were reproducible with all of the preparations tested.
Syntrophins self associate (43,45,46,48) and the larger oligomers can be
collected by centrifugation. Oligomerization and precipitation in the centrifuge for Syn A
in different Ca2+ concentrations or in EGTA is shown in Figure 2.3. Though
approximately 20% of the protein precipitated in the presence of EGTA, the majority of
the protein precipitated at Ca2+ concentrations at or above micromolar. This difference is
statistically significant. Figure 2.4 summarizes the precipitation observed for all the
proteins tested namely Syn, Syn A, Syn B, Syn H, PH1, PH2 and PDZ in presence of
100 µM Ca2+ and 100 µM EGTA. [His]6-green fluorescent protein GFP (81) and MBPLacZα (22) were used as controls for His-Tag and maltose binding fusion proteins,
respectively, and as expected, neither shows appreciable aggregation. Figure 2.4
shows that Syn, Syn A, Syn H, and PH1 aggregate in Ca2+ while other proteins, namely
Syn B, PH2, and PDZ, which did not show any significant precipitation are shown in
Figure 2.5. Thus fusion proteins containing the PH1 domain precipitate in a Ca2+dependent manner. Though Syn H shows less precipitation as compared to other PH1
domain containing fusion proteins, it should be noted (see Figure 2.1) that Syn H has
only the N-terminal portion of the PH1 domain (PH1a) and lacks C-terminal sequences
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Figure 2.2 Purity of the fusion proteins used.
Two micrograms of each fusion protein with the tag intact was applied to 12% sodium
dodecylsulfate-polyacrylamide gel electrophoresis and stained with Coomassie brilliant
blue. The molecular weight of the markers, in kilodaltons, is shown to the left. The arrow
to the right shows the position of full length PH2.
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Figure 2.3 Syn A precipitates in a Ca2+ dependent manner and the Ca2+ chelating
reagent, EGTA inhibits it.
The ultracentrifuge oligomerization assay was performed as described in Materials and
Methods. Full bar length represents total protein. Open bars (white), percent protein in
the supernatant, closed bars (black), percent protein in the pellet. The standard error of
the mean (of duplicates) is given as error bars in each graph. The amount of Ca2+ given
here is the calculated, free concentration after adding Ca2+ to 0.1 mM EGTA in the
buffer.
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Figure 2.4 Extent of precipitation of Syn, Syn A, Syn H, Syn B, PH2, PDZ, and PH1 in
the presence or absence of Ca2+.
Extent of precipitation of Syn, Syn A, Syn H, and PH1 in a Ca2+ dependent manner.
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Figure 2.5 Extent of precipitation of Syn B, PH2, PDZ, GFP, and Laczα in a Ca2+
dependent manner.
Syn B, PH2, PDZ, and the controls used for His-Tag and MBP fusion proteins, GFP and
MBP-LacZα do not show significant precipitation. The labels are as defined in Figure
2.3. The standard error of the mean (of duplicates) is given as error bars in each graph.
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(PH1b). To show that these results were not artifacts caused by prolonged dialysis or
centrifugation, freshly dialyzed protein was centrifuged to remove any aggregate and
this was briefly incubated with Syn-Sepharose. Figure 2.6 confirms the localization of
the syntrophin-syntrophin interaction as shown previously in Figure 2.4. Syn, Syn A,
Syn H, PH1 show binding to Syn-Sepharose while Syn B and PDZ did not show any
binding. CNBr-activated Sepharose-4B without any protein coupled to it was used as a
negative control. Other fusion proteins such as PH2 also did not show any binding (data
not shown).
The syntrophin-syntrophin interaction is further localized in Figure 2.7. Syn, Syn
A, Syn H, and PH1 show binding to PH1-Sepharose while PH2 did not show any
binding. None of the fusion proteins bound significantly to the control Sepharose
(lacking PH1). The combined results of Figure 2.6 and 2.7 show that the sequences
present in the PH1 fusion protein are necessary and sufficient for syntrophin-syntrophin
interaction. These also demonstrate that PH2 and PDZ domains do not play an obvious
role in syntrophin-syntrophin interactions.
Ca2+-calmodulin has been shown to bind the N-terminal sequences of the PH1
domain (54), which are also involved in oligomerization. The effect of calmodulin on the
syntrophin-syntrophin interaction was also tested. PH1 was incubated with PH1Sepharose in the presence or absence of calmodulin in the presence of 100 µM Ca2+ or
100 µM EGTA. Inhibition of the PH1-PH1 interaction by calmodulin is shown in Figure
2.8. While Ca2+ enhances the PH1-PH1 interaction, calmodulin inhibits it in Ca2+ or
EGTA. Figure 2.9 shows the precipitation of Syn A at different concentrations of
calmodulin in the presence of 100 µM Ca 2+ or 100 µM EGTA. In Ca 2+, calmodulin
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Figure 2.6 Localization of the region involved in the oligomerization of syntrophin.
Syn, Syn A, Syn H, PH1 show binding to Syn-Sepharose. (-) represents controlSepharose (no protein coupled), (+) represents Syn-Sepharose. To the right are two
arrows; the upper shows the molecular weight of Syn B, the lower shows the molecular
weight of PDZ which do not show binding to Syn-Sepharose.
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Figure 2.7 Syntrophin’s self-association is localized to the PH1 domain containing
sequences.
Syn, Syn A, Syn H, PH1 show binding to PH1-Sepharose. (-) represents controlSepharose, (+) represents PH1-Sepharose. The arrow to the right shows molecular
weight of PH2, which do not bind to PH1-Sepharose.
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Figure 2.8 Calmodulin inhibits syntrophin self-association in the presence or absence of
Ca 2+.
Calmodulin inhibits syntrophin self-association in the presence or absence of Ca 2+.
PH1-Sepharose was incubated with the PH1 fusion protein in the presence (+) and
absence (-) of calmodulin in the presence of 100 µM Ca2+ or 100 µM EGTA.
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Figure 2.9 Precipitation Syn A at different concentrations of calmodulin in the presence
of Ca2+ or EGTA.
Precipitation of Syn A (using the ultracentrifuge oligomerization assay) at different
concentrations of calmodulin in the presence of 100 µM Ca2+ (open circles) or 100 µM
EGTA (closed squares). The standard error of the mean is given as error bars. The
dotted line shows that the breakpoint in the titration occurs near one calmodulin per
syntrophin.
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reduces the precipitation of Syn A from 64% to 14% in a dose-dependent manner. In
addition, Figure 2.9 shows that calmodulin also inhibits precipitation of Syn A in EGTA
over a similar concentration range. For both curves, a sharp break occurs at 0.65 mol
calmodulin / mol syntrophin suggesting that a single calmodulin binds to cause inhibition
of the precipitation.
Nickel has been reported to induce oligomerization of proteins containing the
[His]6-Tag and removal of this affinity tag by treatment with endoproteinase Xa
abolished the ability of the proteins to form oligomers (82). Since Syn, Syn A, and PH1
are all His-Tag fusion proteins, to show that the observed precipitation was not due to
the affinity tag, these fused sequences were digested using endoproteinase Xa to test
whether they contributed to the precipitation. The experiment was performed with the
digested protein and compared with the undigested protein. Both the digested and
undigested proteins precipitated to a similar extent in a Ca2+ dependent manner (data
not shown). That PH2, PDZ, and GFP (also His-Tag fusion proteins, see Figure 2.4) do
not precipitate confirms that precipitation is not due to His-Tag sequences.
Syntrophin oligomerizes in Ca2+ and, to a lesser extent, in EGTA; to determine
the size of Syn in presence of Ca2+ or EGTA, His-Tag Syn A was subjected to size
exclusion chromatography on Sepharose 4B. Figure 2.10a (lower panel) shows that in
the presence of Ca2+, Syn A forms oligomers of several different sizes but 17% of the
protein is larger than a 20 mer (>670kDa). When calmodulin was added to Syn A (upper
panel) in the presence of Ca2+, it effectively inhibited oligomerization of Syn A resulting
in protein that was predominantly present as monomeric to octameric forms. When a
similar experiment was repeated in the presence of EGTA, protein was
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Figure 2.10 Size exclusion chromatography of Syn A in presence of Ca 2+ and in EGTA.
The column was run as described in the methods. The dashed lines show the position
of molecular weight standards thyroglobulin, (TH); β-galactosidase, (BG); and carbonic
anhydrase, (CA) on the chromatogram for reference. The numbers in the parentheses
indicate molecular weight of the standards. The arrows indicate the size of different
oligomers of Syn A on the chromatogram also for reference.
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predominantly present as monomeric to decameric forms even in the absence of
calmodulin as shown in Figure 2.10b. The small peak at fraction number 16, which
represents protein larger than a 20 mer, could account for the small amount of protein
which precipitates in the ultracentrifugation experiments described earlier. When
calmodulin was added to Syn A in the presence of EGTA, it prevented oligomerization
and most of the protein was present at sizes consistent with a monomer.
The PH1 domain of syntrophin has been reported to bind Ptdlns4,5P2 (52). Other
experiments showed that the presence of Ptdlns4,5P2 did not have any effect on
oligomerization of Syn (data not shown) suggesting that lipid binding does not alter
syntrophin’s oligomeric state.

Discussion
α-Syntrophins were known to self-associate and associate with other syntrophins
(43,45,46,48). A consistent level of aggregation of the syntrophins in the
immunoprecipitation experiments was observed by Ahn et.al (43). In vitro translated α1syntrophin has been shown to bind to all the three components of the syntrophin triplet
in the overlay experiment by Yang et.al (45). The binding of α1-syntrophin with both β1
and β2 syntrophins has been previously seen in the overlay experiments by Madhavan
et.al (46). Peters et al. (44) have shown that pairs of different syntrophins occur in vivo.
This oligomerization was poorly characterized. Recently, it has been shown that the
PH1 domain of mouse α1- syntrophin binds Ptdlns4,5P2 (52). Syntrophin’s PDZ domain
is known to form a dimer (52) and thus was thought to play a role in the oligomerization
of syntrophin. The syntrophin sequence has a leucine approximately every seventh
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residue at its N-terminus from amino acid 107 to 137 similar to the leucine zipper motif
(where leucine is present at exactly every seventh residue). Leucine zippers are known
to mediate protein-protein interaction raising the possibility that this leucine zipper could
function as an oligomerization motif of syntrophin. But in none of the experiments was
[His]6-PDZ, which contains the leucine-rich sequence, found to bind syntrophin or
aggregate in the ultracentrifugation experiments. It may however account for the PDZ
dimerization reported by others (52).
Here, we have shown that the PH1 domain containing sequence of α1-syntrophin
is required for the oligomerization of syntrophin, which occurs in a Ca2+ dependent
manner (Figure 2.4 and 2.6), and that micromolar concentrations of Ca2+ increase
oligomerization (Figure 2.3). Conversely, Ca2+ chelating agents such as EGTA inhibit
oligomerization (Figure 2.3). Since syntrophin alone, in the absence of calmodulin,
responds to Ca2+, Ca2+ must bind directly to syntrophin to cause this effect. Since Ca2+
affects even constructs as small as PH1, Ca2+-binding must occur somewhere within
these sequences. The PH domain of Dbl has been shown to bind Ca2+ with a Kd of 10
µM (83). It is curious to note that Ca2+ also regulates the oligomerization of other
proteins such as actin (84) and tubulin (85).
Oligomerization does not occur with fusion proteins lacking the PH1 domain
(Figure 2.5). Fusion proteins containing an intact PH1 domain precipitate to a larger
extent than does Syn H which lacks C-terminal sequences (PH1b) of the PH1 domain
(Figure 2.4). This may suggest that oligomerization is primarily a property of the Nterminal sequences of the PH1 domain (PH1a) or adjacent sequences. Interestingly,
fusion proteins containing the PH2 domain do not seem to play a role in the
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oligomerization of syntrophin (Figure 2.4 and 2.7). Non-PH1 domain sequences do not
oligomerize (Figure 2.3 and 2.6).
We have also shown that the PH1 domain containing sequence alone is capable
of self-association (Figure 2.7). Calmodulin inhibits the PH1-PH1 interaction (Figure 2.8)
and inhibition does not require Ca2+ (Figure 2.8 and 2.9). This agrees with the
observation by Iwata et.al. (54) that calmodulin binds to N-terminal sequences of PH1
domain. However, Iwata et.al. (54) found that calmodulin binding to this region was
Ca2+-dependent, while we had previously found it to be Ca2+-independent. These results
confirm that calmodulin binding to this region is Ca2+-independent. Figure 2.9 shows
that calmodulin inhibits oligomerization in the presence or absence of Ca2+. Thus, Ca2+calmodulin or apocalmodulin (Ca2+-free) can prevent self-association of the PH1 domain
containing sequences and hence oligomerization of syntrophin. A single calmodulin
apparently binds per syntrophin to inhibit syntrophin self-association (Figure 2.9).
We have also shown that when syntrophin oligomerizes in the presence of Ca2+
much of the protein is larger than a 20-mer (>670 kDa). It also forms several species of
syntrophin oligomers such as 5-mer, 10-mer etc. The presence of calmodulin effectively
prevents this oligomerization, converting the protein from 20-mer and larger to
predominantly the monomer and hence shifting the peaks to the right on the
chromatogram (Figure 2.10a). The peaks actually shift in both directions. When
calmodulin is added to Syn A, Syn A can no longer form large aggregates and hence
shifting the peak to the right on the chromatogram but because calmodulin binds to it,
the molecular weights of the complexes increase, shifting the peaks slightly to the left
on the chromatogram.
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In the presence of EGTA, protein is predominantly present as monomeric to
decameric forms (Figure 2.10b). When calmodulin is added to Syn A in presence of
EGTA, it prevents oligomerization converting the protein to predominantly a monomer.
The oligomerization of syntrophin is complex and a model depicting this oligomerization
process is presented in Figure 2.11. This model suggests that the oligomerization of
syntrophin, denoted by (syn*)p, where P represents polymeric forms of syntrophin occurs
by binding of Ca2+-syntrophin (denoted by an asterisk), and this process is regulated by
Ca2+ (Figure 2.3, 2.4, and 2.6) and calmodulin (Figure 2.8 and 2.9). Calmodulin inhibits
the oligomerization in a Ca2+-independent manner (Figure 2.9). Syn in this model is not
meant to strictly refer to monomeric syntrophin but to include this and simple oligomers.
The somewhat larger oligomers (Figure 2.10b) (up to decamer) which occur in the
absence of Ca2+ are shown as (Syn)O. In our previous report (48), another form of
syntrophin is shown, indicated as SynX, which occurs at high concentrations in absence
of Ca2+ that does not bind dansyl-calmodulin. This form is not shown in this scheme
because it was not investigated in the experiments presented and is currently less welldefined but may represent a predominance of (Syn)O at high protein concentrations.
From these in vitro results, the state of syntrophin in vivo may be inferred.
Calmodulin is present in many tissues as high as micromolar and is probably in
sufficient concentration to inhibit or limit the oligomerization of syntrophin. In the resting
muscle, Ca2+ would be submicromolar in concentration and this would also limit
aggregation. The calmodulin bound would be the Ca2+-free, apocalmodulin conformer
(55). As intracellular Ca2+ increases, preceding and during muscle contraction, this Ca2+

41

Ca2+
(Syn)O

Syn
+
CaM

CaM1.Syn
+
CaM

CaM2.Syn

Syn*
+
CaM CaM*

EGTA

(Syn*)P

Ca2+
CaM*1.Syn*
+
CaM*

EGTA

Ca2+

CaM*2.Syn*

EGTA

Figure 2.11 A model depicting oligomerization of syntrophin.
In this model calcium bound forms of syntrophin and calmodulin (CaM) are denoted with
an asterisk (*). The polymeric forms of Ca2+-syntrophin are denoted as (Syn*)p. The
smaller oligomeric forms of syntrophin in the absence of Ca2+ are shown as (Syn)O.
CaM1.Syn and CaM2.Syn represent calmodulin binding to one or both of the two sites
known (54) at the N-terminus of syntrophin.
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could bind to syntrophin and favor syntrophin aggregation. Additionally, as Ca2+ binds
calmodulin, calmodulin would be able to bind to other, more numerous cell proteins,
which bind only the Ca2+-calmodulin conformer. Thus, Ca2+-calmodulin could be bound
elsewhere, allowing syntrophin's oligomerization. Thus, one can envision syntrophin as
monomeric in the resting cell and oligomeric in the contracting muscle. The oligomeric
state of syntrophin may be important to maintaining the clusters of ion channels at the
neuromuscular junction during contraction. Alternatively, syntrophins may respond to
Ca2+ during contraction in a way that makes the protein complexes which contain it
more resistant to the contractile forces. Indeed, it is now apparent that the dystrophinactin (77), syntrophin-dystrophin (46), and syntrophin-syntrophin interactions all are
responsive to Ca2+ and calmodulin suggesting that during muscle contraction, the
protein-protein interactions within the dystrophin glycoprotein complex are altered and
probably rearrange.
Phosphotidyl inositol-4,5 bisphosphate binds the PH1 domain (52) but it does not
influence oligomerization. This would not be predicted from other PH domains,
particularly of both dynamin isoforms, that require oligomerization for high affinity
phosphoinositide binding (86). Since Ptdlns4,5P2 did not affect oligomerization, it is
clear that it does not regulate this syntrophin activity. What role(s) it plays remains to be
elucidated. Binding this lipid probably serves the role of localizing syntrophin to the
membrane surface. Syntrophins bind Na+-channels (60), NO-synthetase (57,58),
dystrophin, α- and γ- sarcolglycans (46), SAPK3 (59) and to themselves. This selfassociation could bring together cellular signaling components and ion channels.
Calmodulin can thus inhibit syntrophin oligomerization in a Ca2+-independent manner
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(this report) and inhibit syntrophin’s interaction with dystrophin in a Ca2+-dependent
manner (48). Furthermore, since Ca2+ promotes aggregation of syntrophin even in the
absence of calmodulin, it must be able to bind to syntrophin itself and alter its chemical
and physical properties. This agrees with our previous observation of Ca2+ binding by
syntrophin.

44

Chapter 3. Mouse α 1-Syntrophin Binding To Grb2: Further Evidence
Of A Role For Syntrophin In Cell Signalingii

Introduction
Syntrophins are a group of peripheral membrane proteins first identified in
Torpedo postsynaptic membranes (74). Syntrophins have been found to be closely
associated with dystrophin (75), the protein product of the Duchenne muscular
dystrophy gene locus (75,87). In skeletal muscle, dystrophin and syntrophins are found
in a complex with other proteins and glycoproteins, the dystrophin glycoprotein complex
or DGC1 (6,20) whose defects cause Duchenne, Becker, various limb girdle, and other
muscular dystrophies. Syntrophins are a multigene family of homologous proteins.
Three syntrophin isoforms, α1, β1, and β2, are products of different genes (58,88-90).
The α1-syntrophin is primarily expressed in striated muscles and brain, while the βsyntrophins are ubiquitous in mammalian tissues (43). Each of the syntrophins contains
two pleckstrin homology (PH) domains, an N-terminal PH1 domain and a PH2 domain
(see Figure 3.1). The PH1 domain of α1-syntrophin has been reported to bind
phosphatidylinositol 4,5-bisphosphate (PtdIns4,5P2) (52). Recently, this domain has
also been shown to be involved in the oligomerization of syntrophin in vitro in a Ca2+dependent manner. in which this ~90 amino acid motif was identified: the Postsynaptic

ii

Reproduced with permission from Biochemistry, Oak, S. A., Russo, K., Petrucci,

T. C., and Jarrett, H. W. (2001) 40(37), 11270-8. Copyright [2001] American Chemical
Society.
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Figure 3.1 Diagrammatic representation of fusion proteins containing α1-syntrophin and
Grb2 sequences.
The darkly shaded portion shows the location of proline rich motifs in syntrophin. The
lighter shading highlight the SH3 domains of Grb2. Numbers in parentheses represent
the amino acid sequences present in each fusion protein.
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density protein (PSD-95), the Drosophila disks-large protein (Dlg), and the Zona
Occludens 1 (ZO-1) protein. Calmodulin inhibits oligomerization in a Ca2+-independent
manner (91). The amino terminal PH domain is interrupted by an inserted PDZ domain.
The PDZ domain is found in membrane proteins and was named for the first three
proteins Syntrophin's PDZ domain has been shown to bind neuronal nitric oxide
synthetase (57,58), muscle and nerve voltage gated Na+ channels (60), and the MAP
kinase, SAPK3 (59). Syntrophins also bind calmodulin (53). A domain unique to
syntrophins, the SU domain has been shown to bind Ca2+-calmodulin (48) and the SU
domain in addition to other sequences in the C-terminal of the protein binds to
dystrophin. Ca2+-calmodulin binding inhibits the syntrophin-dystrophin interaction (48).
The N-terminal of the PH1 domain and the N-terminal of the PDZ domain have been
reported to bind calmodulin (54) in a Ca2+-independent manner (48,91). Thus,
syntrophins act as adapters, in between the dystrophin complex of proteins and
components of the cell signaling apparatus.
Grb2 (growth factor receptor bound 2), the human homologue of the nematode
Caenorhabditis elegans protein Sem-5, is an adapter protein consisting of one src
homology (SH) 2 domain flanked by two SH3 domains. The N-terminal SH3 domain
stretches from amino acids 5 to 55, the SH2 domain from 60 to 158 and the C-terminal
SH3 domain from 164 to 214. This structure suggests that Grb2 is capable of binding
phosphotyrosine proteins through its SH2 domains, while its SH3 domains interacts with
proteins possessing PXXP motifs. While investigating the known interaction (45, 72)
between Grb2 and β-dystroglycan, we discovered that syntrophin was also a Grb2binding protein. The N-terminus of syntrophin contains two proline-rich regions that
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could interact with the SH3 domains of signaling proteins, namely:
PADGPGPEPEPAQLNGAAEPGAAPPQLPEAL (α-syntrophin 44-75)
WASPPASPLQRQPSSPGPQPRNLSEAKHVSLKMAYVSRRCTPTDPEPRY (181 to 229)

These are located in the intervening sequences between the PH1a and PDZ
domain sequences and between the PDZ and PH1b domains and overlapping the Nterminus of the latter.
In this chapter, we have characterized the interaction of the mouse α1-syntrophin
with the adapter protein, Grb2.

Experimental procedures

Materials
Antibodies against recombinant Grb2 (anti-Grb2), GST (anti-GST) and αsyntrophin were produced in rabbit and purified by affinity chromatography. Mouse
monoclonal Grb2 antibody was from Transduction Laboratories. Crk-L rabbit polyclonal
antibody was from Santa Cruz Biotechnology. S-protein alkaline phosphatase conjugate
was from Novagen. Goat anti-rabbit IgG (H+L)-alkaline phosphatase conjugate, goat
anti-mouse IgG (H+L)-alkaline phosphatase conjugate and goat anti-rabbit IgG (H+L)horseradish peroxidase conjugate were from BioRad. Ni2+-NTA-agarose was from
Qiagen. Cyanogen bromide pre-activated Sepharose was from Sigma. All other
chemicals were of the highest purity available commercially.
Dystrophin glycoprotein complex (DGC) was partially purified from digitonin
solubilized rabbit skeletal muscle using the procedure of Ervasti, et al. (7) up through
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the succinylated wheat germ agglutinin (sWGA) chromatography. Aliquots were stored
frozen at –85°. DGC was further fractionated by electrophoresis on 4-15% gradient
sodium dodecylsulfate polyacrylamide gels and blotted to nitrocellulose as previously
described (46). The gel blots were then overlaid with Grb2 as described under Overlay
Experiments below. Gel blots were also stained with specific antibodies for αsyntrophin, α- and β-dystroglycan, and α-sarcoglycan to confirm the identity of bands
interacting with Grb2.

Fusion proteins
The syntrophin fusion proteins [His]6-Syn, [His]6-Syn A, maltose binding protein
(MBP) fusions MBP-Syn B, MBP-Syn H, and MBP-Syn I were prepared as described
previously (48). pET32 plasmid constructs for PH1, PH2, and the PDZ domain were the
generous gift from Drs. Steven Gee and Stan Froehner, (Department of Physiology,
University of North Carolina, Chapel Hill). pET32 plasmids encoding [His]6-thioredoxinPH1, -PH2, and –PDZ were used to express proteins referred to as [His]6-PH1, -PH2,
and -PDZ (60). The His-Tag fusion proteins were purified by using Ni2+-NTA-agarose
from Qiagen as described earlier (48). The MBP fusion proteins were purified using the
batch method described previously by Jarrett and Foster on amylose resin (77). GSTGrb2, GST-Grb2-N-SH3 (amino acids 1-54), and GST-Grb2-C-SH3 (amino acids 163217) domains, (kindly provided by Dr. O. Segatto, Instituto Regina Elena, Roma, Italy),
GST-βC1 (rabbit β−dystroglycan coding amino acids 787-895) (92) were all expressed
in E. coli BL21 strain and purified by affinity chromatography on glutathione-agarose
beads (Amersham Pharmacia Biotech) as described elsewhere (92,93). The purity of
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the proteins was determined by 12% SDS-polyacrylamide gel electrophoresis using the
method of Laemmli (78). The major bands of the fusion proteins were of expected size
and relatively high purity (data not shown). The Bradford assay (79) was used to
determine the protein concentrations using bovine serum albumin as the standard.

Overlay experiments
The fusion proteins Syn, Syn A, Syn B, Syn H, PH1, MBP-LacZα, and [His]6green fluorescent protein (GFP) were applied to electrophoresis on a 12% SDS-PAGE
gel, and electroblotted onto nitrocellulose paper. The paper was then blocked with 10
mg/ml BSA in TTBS (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl and 0.2%Tween-20). After
washing extensively with 1 mM CaCl2 in BSA/TTBS (1 mg/ml BSA in TTBS), the blot
was overlaid with 0.1 mg/ml GST-Grb2 for 2h in the presence of 1 mM Ca2+. The blot
was then washed extensively with Ca2+/BSA/TTBS, and incubated with affinity purified
anti-GST (1:5000 dilution). Goat anti-rabbit IgG (H+L)-alkaline phosphatase conjugate
(1:1000 dilution, BioRad) was used, following the primary antibody. The blot was
developed using 1:100 dilution each of 30 mg/ml NBT (in 70% dimethylformamide) and
15 mg/ml BCIP (in 100% dimethylformamide) into buffer AP (0.1M NaHCO3, 1mM
MgCl2, pH 9.8). Alternatively, after primary antibody and washing as above, blots were
probed with 1:3000 diluted goat anti-rabbit IgG (H+L)-horseradish peroxidase conjugate,
washed as above, and developed for chemiluminescence by incubating the blot in a
mixture of 15 ml of solution A (90 mM Coumaric acid and 250 mM Luminol, 1 M Tris
HCl, pH 8.5) and 15 ml solution B (7.2 µl H2O2 in 1 M Tris HCl, pH 8.5) in the dark room
and then exposing it to Kodak Scientific Imaging film. MBP-LacZα and (His)6-GFP were
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used as controls for maltose and His-Tag fusion proteins, respectively. A similar
experiment was performed to test binding of Grb2 to syntrophin from partially purified
dystrophin glycoprotein complex. Bovine serum albumin was used as a control for this
experiment.

Immunoprecipitation
Samples in phosphate buffered saline (0.13 M NaCl, 2.68 mM KCl, 5.37 mM
Na2HPO4, 1.76 mM KH2PO4, pH 7.4) containing 1% Triton X-100 were prepared by
incubation with protein A-Sepharose at 40 for 1h. The supernatants were incubated with
100 µl of fresh protein A-Sepharose with anti-syntrophin or anti-MBP polyclonal
antibodies at room temperature for 1h and then on ice for 30 min. The beads were
washed three times with phosphate buffered saline containing 1% Triton X-100. The
bound proteins were eluted by boiling in SDS-PAGE sample buffer and separated on a
4-15% gradient sodium dodecylsulfate polyacrylamide gel (BioRad) and blotted to
nitrocellulose membrane as described previously (80). The blots were then analyzed by
using different antibodies and were developed using the enhanced chemiluminescence
method.

Solid phase binding assays
0.9 mg of GST-Grb2 (0.9 mg/ml) was coupled to 1 g of cyanogen bromideactivated Sepharose (Sigma) using procedures recommended by the manufacturer
(Pharmacia). The support was then washed with the coupling buffer (0.1 M NaHCO3, pH
8.3, 0.5 M NaCl) and blocked for 2h with 0.1 M Tris-HCl, pH 8, 0.5 M NaCl. The amount
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of the protein coupled (0.115 mg Grb2/ml 50% slurry Sepharose) was determined by
the difference in the ultraviolet absorption of the added protein and that recovered from
coupling in the wash fractions. For negative controls, CNBr-activated Sepharose was
used to which either no protein or glutathione-S-transferase (GST) was coupled.
200 µl of a 50% slurry of Grb2-Sepharose containing 23 µg Grb2 was
equilibrated with buffer A (50 mM Tris, pH 7.5, 100 mM KCl) containing 0.1 mM EGTA
and then incubated with different fusion proteins (25 µg) or rabbit skeletal muscle
extract prepared in a manner similar to the immunoprecipitation experiment. Incubation
was for 1h at room temperature and for 30 min on ice with gentle mixing in a final
volume of 200 µl. For control, Sepharose without any protein coupled to it or Sepharose
with glutathione–S-transferase coupled to it was used. After the incubation, Grb2Sepharose was washed three times with 0.5 ml of 1 mg/ml BSA/TTBS. The protein was
eluted using 60 µl of 2x Laemmli sample buffer (78). Samples were heated for 5 min at
950. The samples were then centrifuged for 5 min at room temperature to remove the
resin, applied to electrophoresis on a 12% SDS-PAGE gel (78), and electroblotted onto
nitrocellulose paper (80). The paper was then blocked with 10 mg/ml BSA in TTBS.
After washing extensively with 1 mg/ml BSA/TTBS, the blot was incubated with affinity
purified anti-MBP (1:1000 dilution) for MBP fusion proteins or T7 monoclonal antibody
(Novagen, 1:10,000 dilution) for His-Tag fusion proteins. Goat anti-rabbit IgG (H+L)alkaline phosphatase conjugate and goat anti-mouse IgG (H+L)-alkaline phosphatase
conjugate (both 1:1000 dilution) were used for the rabbit and mouse primary antibodies,
respectively. For fusion proteins containing S-Tag, namely PH1, PH2 and PDZ, Sprotein alkaline phosphatase conjugate (1:5000, Novagen) was used.
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Surface plasmon resonance
SPR assays were performed using a BIAcore instrument (BIAcore X) equipped
with a two flow cell sensor chip, using purified Grb2 or Grb2-C-SH3 or Grb2-N-SH3
domain GST fusion proteins. Proteins were immobilized by covalent coupling to CM-5
sensor chips (research grade) (BIAcoreAB) after activation of the carboxymethylated
dextran surface by a mixture of 0.05 M N-hydroxysuccinimide and 0.2 M N-ethyl-N’-3(dimethylaminopropyl) carbodiimide hydrochloride. The reaction was performed by
injecting 45 µg/ml of Grb2 in 10 mM acetate buffer, pH 4.8 at a flow rate of 10 µl/min at
25o for 7 min. Residual activated groups were blocked with 1 M ethanolamine-HCl, pH
8.5. Immobilization resulted in about 4000 resonance units (RU) Grb2 protein. Binding
assays were performed in HBS (10 mM HEPES, 0.15 M NaCl, 3 mM EDTA, 0.5%
surfactant P20, pH7.4) with a flow rate of 2, 5, 10, 15, 20 µl/min. The soluble ligand
(Syn) was applied in the range of concentration of 15.5 nM – 82.7 µM. At the end of the
sample plug, HBS buffer was allowed to flow past the sensor surface to allow
dissociation. The sensor surface was regenerated for the next Syn sample using a 30–
120 sec pulse of regenerating buffer (50 mM NaOH) at a flow rate of 20 µl/min. Non
specific binding on the sensor surfaces and mass-transport problems were avoided by
flowing the same solution past the two sensor surfaces in sequence and using different
flow rates. The response was monitored as a function of time (sensogram) at 25o. The
integrity of immobilized proteins was tested with anti-Grb2 antibody.
The data evaluation was carried out using a BIAevaluation software version 3.0,
following the manufacturer’s instructions. The kinetics constants were calculated by
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non-linear regression of data using the pseudo first order rate equation as described in
detail by Herzog et al. (94).

Solid phase immunoassay
To measure the binding of GST-Grb2 to Syn A, a microtiter assay was used. A
microtiter plate (Dynatech Immulon 1) was coated by incubation of 100 µl/well of 0.05
mg/ml His-Tag Syn or –Syn A for 4h at 40. The plate was then blocked by replacing the
fusion proteins with 300 µl/well of 30 mg/ml BSA in AC7.5 buffer (50 mM Tris-Cl, pH 7.5,
100 mM KCl, 3 mM MgCl2, 1 mM CaCl2). All subsequent operations were at room
temperature and 100 µl/well. After washing the plate three times (5 min per wash) with
AC7.5T/BSA (buffer AC7.5, 0.1 % Tween-20, 1 mg/ml BSA), serial dilutions of each of
GST-Grb2, GST-Grb2-C-SH3, GST-Grb2-N-SH3, or GST were added. The plate was
incubated for 2h. The plate was washed three times as described above and then
incubated with anti-GST antibody for 1h. The plate was washed three more times as
described and incubated with goat anti-rabbit IgG (H+L)-alkaline phosphatase conjugate
(1:1000 dilution, BioRad) for 1h. The plate was then washed once with 1 mg/ml
AC7.5T/BSA followed by two immediate washes of diethanolamine/Mg (10 mM
diethanolamine, 0.5 mM MgCl2). The plate was developed by incubation with 100 µl/well
of 1 mg/ml p-nitrophenylphosphate in diethanolamine/Mg. The absorption at 405 nm
was determined versus time. The concentration giving half maximal response was
calculated and is denoted here as Kd.
For the experiments performed in EGTA, CaCl2 was replaced by EGTA in all the
buffers up to the stage at which the anti-GST antibody was added. After that stage, the
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experiment was continued as specified above using the CaCl2 containing AC7.5T/BSA.

Results
The schematic representation of mouse α1-syntrophin and Grb2 sequences
expressed as fusion proteins is shown in Figure 3.1. The regions of mouse α1syntrophin’s amino acid sequence in each construct are given in parenthesis. The
boundaries of the PH1 domain are not well defined; our PH1 construct contains some
additional sequences as shown in Figure 3.1. Syn, Syn A, PH1, PH2 and PDZ were
produced as His-Tag fusion proteins while Syn B, Syn H and Syn I were produced as
maltose binding fusion proteins. Glutathione S-transferase (GST) fusions of Grb2 and
selected regions of it were also produced. Each fusion protein was affinity purified.
Gel blots of partially purified dystrophin glycoprotein complex bind Grb2 as
shown in Figure 3.2. Coomassie blue staining of the purified dystrophin glycoprotein
complex is shown in the figure. Clearly, the dystrophin glycoprotein complex is only
partially purified and other proteins are present but it is sufficient to determine Grb2
binding. In the Coomassie stain, the syntrophins appear as two bands but the upper,
more intense band is itself a doublet of the two β-syntrophins. The lower, less intense
band is α-syntrophin. The three asterisks show the position, in descending order, of the
α-dystroglycan, the syntrophins, and β-dystroglycan; all bind Grb2. Specific staining with
α-syntrophin, β-dystroglycan and α-dystroglycan antibodies confirm these identities.
The DGC was also probed with dystrophin antibody (NCL-DYS2) from Novacastra (data
not shown). The DGC was also overlaid with GST alone and did not show any binding
(data not shown). β-Dystroglycan (lowermost asterisk) had been previously shown to
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Figure 3.2 Grb2 binds syntrophin in the partially purified dystrophin glycoprotein
complex (DGC) from rabbit skeletal muscle.
Partially purified DGC was applied to electrophoresis on a 4-15% gradient sodium
dodecylsulfate- polyacrylamide gel and electroblotted onto nitrocellulose paper. The blot
was then overlaid with 0.1 mg/ml GST-Grb2 for 2 hr in the presence of 1 mM CaCl2. The
binding was detected with anti-GST antibody. Three asterisks (*) show the positions of
α-dystroglycan, the syntrophins and β-dystroglycan in the descending order. Anti-βDG,
Anti-Syn, Anti-αDG show the bands detected by the β-dystroglycan , α-syntrophin and
α-dystroglycan antibodies, respectively. To the left are shown molecular weight
markers.
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bind Grb2 (95), but this is actually the least intense of the staining observed. αSarcoglycan showed binding to Grb2 in some of the dystrophin glycoprotein complex
preparations we tested (data not shown) though it did not bind Grb2 well in this
particular preparation. Close inspection of its sequence demonstrated that the only
PXXP motifs present are PYNP from amino acid 83 to 86 and PEGP, from amino acid
128 to 131, regions of the protein believed to be on the exterior face of the sarcolemma
(96) and are of questionable relevance to in vivo binding. α-Dystroglycan (uppermost
asterisk) shows the strongest binding to Grb2. Though its sequence contains PXXP
motifs such as PSEP from amino acid 29 to 32, PTLP from amino acid 302 to 305,
PTSP, from amino acid 340 to 343, PIQP from amino acid 382 to 385, PATP from
amino acid 432 to 435 and PRTP from amino acid 451 to 454, this protein is believed to
be on the exterior face of the sarcolemma and therefore, is also of questionable
relevance to in vivo intracellular binding. Therefore, the remainder of this chapter will
focus on this newly discovered (Figure 3.2) interaction with α-syntrophin (middle
asterisk), an intracellular peripheral membrane protein.
In other experiments, the partially purified dystrophin glycoprotein complex was
probed with other antibodies. The uppermost band seen in the Coomassie stained gel in
Figure 3.2 is dystrophin and is detected with a dystrophin antibody (NCL-Dys2 from
Novacastra). It co-migrates with the 250 kDa marker in this gel system although its true
molecular weight is much larger. Dystrophin did not bind Grb2 in any of our experiments
and neither did the other (β, δ, and γ) sarcoglycans. There is a band at about 70 kDa
which does bind Grb2 (Figure 3.2, lane 2) which is near the molecular weight of one of
the shortened dystrophin (DP71) forms but it did not bind dystrophin C-terminal antibody
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and so it is not this protein (data not shown). We made no other attempts to identify it.
To confirm the observed interaction of syntrophin with Grb2, GST-Grb2Sepharose was incubated with rabbit skeletal muscle extract. GST-Sepharose was
used as a control. Although a small amount of syntrophin is present in the flow through,
most of the syntrophin binds to Grb2 (top arrow, Anti-Syn) can be seen in Figure 3.3. βdystroglycan has been shown to bind Grb2 by Yang et al.(95) and is used as a positive
control (middle arrow, Anti-βDG). Anti-CrkL was used as unrelated antibody which
served as a negative control. Grb2 did not show any binding to CrkL and all of the CrkL
was present in the flow through.
To investigate if a complex of syntrophin and Grb2 is present in skeletal muscle
and if this interaction is specific, syntrophin was immunoprecipitated (“S” in Figure 3.4)
from rabbit skeletal muscle extract and results were analyzed by immunoblotting. For
comparison, the irrelevant anti-MBP antibody was also used (“M” in Figure 3.4). The gel
blot of the bound proteins was probed with two antibodies against SH3 domain proteins:
the mouse monoclonal anti-Grb2 -antibody (Trasduction Laboratories) and anti-Crk-L
antibody (Santa Cruz). It can be seen from Figure 3.4 that Grb2 binds syntrophin
(Figure 3.4, anti-Grb2) while Crk does not (Figure 3.4, antiCrkL). The antibody light
chain band in the immunoblot (Figure 3.4, anti-CrkL, lane S) is near the expected size
for Crk but migrates faster on the gel than expected for Crk and faster than the Crk
band detected in the muscle extract used (Figure 3.4 anti-CrkL, lane Cr). Similar results
were also obtained using an anti-Grb2 polyclonal antibody (data not shown), Grb2
bound syntrophin while Crk did not although the muscle extract contained both
proteins(data not shown). Thus, Grb2 binds but not Crk. Syntrophin contains a PQLP
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Figure 3.3 Grb2 binds syntrophin and β-dystroglycan from rabbit skeletal muscle
membrane.
GST-Grb2-Sepharose or GST-Sepharose was incubated with the rabbit skeletal muscle
extract containing 1% Triton X-100 as described in the experimental procedures. Cr
represents crude extract, FT is the fraction not bound by the Grb2-Sepharose, GST
represents GST-Sepharose that was used as negative control, and Grb2 represents the
GST-Grb2-Sepharose bound fraction. The top arrow shows the band detected by αsyntrophin antibody (anti-Syn), the middle arrow shows the band detected by βdystroglycan antibody (anti-βDG), and the bottom arrow shows the band detected by
the CrkL antibody (anti-CrkL). Molecular weight markers are shown to the left.
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Figure 3.4 Immunoprecipitation of Grb2 from rabbit skeletal muscle extract.
Rabbit skeletal muscle extract containing 1% Triton X-100 was incubated with Protein A
Sepharose and α-syntrophin antibody (S) or anti-MBP antibody (M), a negative control.
After extensive washing, bound proteins were eluted with SDS-PAGE sample buffer.
Samples, after electrophoresis and electroblotting, were probed with antibodies for Grb2
(mouse monoclonal, anti-Grb2) and Crk (rabbit polyclonal, anti-CrkL). The positions of
Grb2 (lower arrow) and Crk (higher arrow) are indicated. Heavy and light chains of IgG
are indicated in the middle as Hc and Lc, respectively. The crude extract (Cr) was also
applied to the same gel.
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sequence (69-72), which is similar to a motif known to bind Crk (97). Thus, this
experiment was designed to test if a reasonable alternative SH3 domain protein bound
instead of Grb2. Apparently though, Grb2 binds while Crk does not. The reverse
experiment using mouse monoclonal anti-Grb2 and anti-Crk-L antibody was also
performed to immunoprecipitate syntrophin from rabbit skeletal muscle extract and
showed also that Grb2 but not Crk binds syntrophin (data not shown). This was also
confirmed using muscle extract and syntrophin –Sepharose; Grb2 bound while Crk-L
did not (data not shown).
Figure 3.5 summarizes the Grb2 interaction observed for all the syntrophin fusion
proteins tested, namely Syn, Syn A, Syn B, Syn H, Syn I, PH1, PH2, and PDZ. A typical
experiment is shown in Figure 3.5. Syn, Syn A, Syn B, PH1, and PDZ were briefly
incubated with Grb2-Sepharose in the presence of 1 mM EGTA, since Syn, Syn A, and
PH1 have been shown to oligomerize in the presence of Ca2+ (91). Syn, Syn A, and
PH1 showed binding to Grb2-Sepharose while Syn B and PDZ did not bind (Figure 3.5).
CNBr-activated Sepharose-4B without any protein coupled to it was used as a negative
control. This assay also demonstrated that Syn H and Syn I also bound Grb2 in other
experiments (data not shown).
To confirm the region involved in this interaction, an overlay experiment was
carried out where gel blots of syntrophin fusion proteins were overlaid with Grb2 in the
presence of 1 mM Ca2+. Figure 3.6 confirms the localization of the Grb2-syntrophin
interaction. [His]6-green fluorescent protein (GFP) and MBP-LacZα were used as
controls for His-Tag and maltose binding fusion proteins, respectively, and as expected
neither shows any binding to Grb2. Syn, Syn A, Syn H, Syn I, and PH1 all bind Grb2
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Figure 3.5 Syntrophin’s Grb2 binding region is localized to the proline-rich motifs
adjacent to and overlapping the PH1 domain.
Syntrophin’s Grb2 binding region is localized to the proline-rich motifs adjacent to and
overlapping the PH1 domain. Grb2-Sepharose was incubated with the Syn fusion
protein in the presence of 1 mM EGTA. GST represents GST-Sepharose, Grb2
represents Grb2-Sepharose. To the right are two arrows, the upper arrow shows
molecular weight of Syn B, and the lower arrow shows molecular weight of PDZ which
do not bind to Grb2-Sepharose. To the left are shown molecular weight markers.
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Figure 3.6 Localization of syntrophin’s Grb2 binding region to the polyproline
sequences.
A gel blot overlay experiment was performed as described in the experimental
procedures in the presence of 1 mM CaCl2. Syn fusion proteins were separated by
electrophoresis, blotted to nitrocellulose, and overlaid with GST-Grb2 and the binding
was detected with anti-GST antibody. [His]6-green fluorescent protein (GFP) and MBPLacZα were used as controls for His-Tag and maltose binding fusion proteins,
respectively. To the left are shown molecular weight markers.
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while Syn B, PH2, and PDZ don't. Notice that the two proline-rich regions are separately
expressed in Syn H and Syn I (see Figure 3.1) and that both bind full-length Grb2
(Figure 3.6). Binding occurs to the same proteins in the absence (Figure 3.5) or
presence (Figure 3.6) of Ca2+.
The binding affinity of Syn for Grb2 was determined by surface plasmon
resonance. This experiment unlike all the others in this dissertation was not performed
by Shilpa oak. Sensograms for the binding are shown in Figure 3.7. Similar experiments
were also done for Syn/Grb2-C-SH3 and Syn/Grb2-N-SH3 interactions (data not
shown). The initial part of each curve corresponds to signal of the buffer flowing on
sensor surface. The rising part of the curve (association) results from syntrophin binding
to the Grb2 on the surface of the sensor chip. Finally, buffer alone flows over the chip
and the decreasing signal results as bound syntrophin dissociates. Control experiments
demonstrate that the syntrophin association occurs only when the chip surface contains
Grb2 (data not shown). Increasing concentrations of Syn ranging from 15.5 nM-82.7 µM
were allowed to flow over the sensor surface. The observed association rate constant,
kon (7.89 x 103 M-1 s-1), and the dissociation rate constant, koff (4.44 x 10-3 s-1), was
calculated from the association and dissociation sensorgrams, respectively, using a
simple bimolecular association model (94) and the apparent dissociation constant, Kd,
calculated from the ratio of the rate constants (i.e., koff/kon). For the binding of full-length
syntrophin to full length Grb2 (Figure 3.7), Kd = 563 ±15 nM. For the binding of fulllength syntrophin to the two separate SH3 domains of Grb2, Kd = 351 ± 4 nM and 438 ±
4 nM for Grb2-N-SH3 and Grb2-C-SH3, respectively (data not shown).
To confirm the binding affinity of syntrophin for Grb2, [His]6-Syn or -Syn A was
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Figure 3.7 Surface plasmon resonance profiles of the binding of soluble Syn to Grb2
immobilized to the sensor chip.
Individual curves from bottom to top were obtained with Syn concentrations ranging
from 15.5 nM to 82.7 µM. Association and dissociation phases were started at 0 s and
at 240 s, respectively.
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used to coat the wells of a microtiter plate, and the binding of GST-Grb2 was assessed.
The results in Figure 3.8 demonstrate an interesting phenomenon – that Syn A binds
Grb2 with considerably higher affinity than does the full-length Syn. For Syn, the affinity
was 355 ± 25 nM in reasonably good agreement with the value (563 nM) measured in
the surface plasmon resonance experiment (Figure 3.7). However, Syn A bound with an
apparent affinity of 35 ± 10 nM, an order of magnitude higher affinity (both are the
average ± standard deviation for three separate determinations). Syn A was also mixed
with Syn B to reconstitute the complete sequence in two parts and this mixture was
assayed for binding to Grb2. The affinity was not significantly different from that
observed for Syn A alone (data not shown).
To determine if Grb2 was binding preferentially to either Syn H or Syn I, [GST] –
Grb2 or GST alone was used to coat the wells of a microtiter plate, and overlaid with
MBP-Syn H or MBP-Syn I. The binding was detected with anti-MBP antibody. The
results in Figure 3.9 demonstrate that Syn H and Syn I bind Grb2 with a Kd of 182 nM
and 171 nM, respectively. The issue of whether the Grb2-C-SH3 or Grb2-N-SH3
domains bound preferentially to either Syn H or Syn I was addressed in a similar
experiment (data not shown). The result was that Grb2-C-SH3 is bound to higher levels
by both Syn H and SynI but both Grb2 SH3 domains bind to both regions of syntrophin
and the affinities are quite similar. Thus, both syntrophin sequences show some
preference for the Grb2-C-SH3, but the differences are not large. A peptide containing
polyproline sequences in Syn H -EPGAAPPQLPEALLLQ (63-78) was synthesized and
used in an ELISA experiment. It did not inhibit the interaction between Syn A and Grb2
(data not shown), supporting the results observed in Figure 3.9 that the polyproline sites
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Figure 3.8 Grb2 binds to Syn A with higher affinity than to full-length syntrophin.
Solid phase immunoassay was performed on Syn or Syn A coated mocrititer plates as
described in experimental procedures. Binding of GST-Grb2 was detected by using antiGST antibody. Absorption 405 nm measures the amount of GST-Grb2 bound by
syntrophin (circles) and Syn A (squares). The data were scaled by subtracting blank
values (obtained using GST coated plate wells) and defining the maximum signal for
each data set as 100%.
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Figure 3.9 Grb2 binds to Syn H and Syn I with similar affinities.
Solid phase immunoassay was performed on GST-Grb2 coated microtiter plates as
described in experimental procedures. Binding of MBP-Syn H (open circles) or MBP–
Syn I (closed circles) was detected by using anti-MBP antibody. Absorption 405 nm
measures the amount of MBP-Syn H, MBP-Syn I bound by Grb2. The data were scaled
by subtracting blank values (obtained using GST coated plate wells).
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present in both Syn H and Syn I are required for the high affinity Grb2 binding.
To further localize the Grb2-syntrophin interaction, [His]6-Syn A was used to coat
the wells of a microtiter plate, and the binding of GST-Grb2, GST-Grb2-C-SH3, and
GST-Grb2-N-SH3 was assessed in the presence of 1 mM EGTA. Binding was detected
using the anti-GST antibody. A typical experiment is presented in Figure 3.10.
Averaging the data from three different experiments gave half maximal binding at 35 ±
10 nM Grb2, 80 ± 10 nM for Grb2-N-SH3, and 60 ± 10 nM for Grb2-C-SH3. This assay
was also used to confirm that other fusion proteins, including Syn I and Syn H, bound
Grb2. Furthermore, experiments in Ca2+ or EGTA gave similar binding affinities showing
that this interaction is independent of Ca2+ (data not shown).
Syntrophin has been shown to bind dystrophin but this binding has no effect on
the syntrophin-Grb2 interaction, since we find that the DysS9 fusion protein, containing
the C-terminus of dystrophin that binds syntrophin (98), does not interfere with Grb2
binding (data not shown). The N-terminal of the PH1 domain and the N-terminal of the
PDZ domain have been reported (54) to also bind calmodulin. Binding of calmodulin to
syntrophin in the presence or absence of Ca2+ also does not influence the Grb2
interactions (data not shown). Phosphatidylinositol-4,5 bisphosphate binds syntrophin's
PH1 domain (52) but it does not influence the syntrophin-Grb2 interaction (data not
shown). Binding this lipid probably serves the role of localizing syntrophin to the
membrane surface.
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Figure 3.10 Syn A binds best to Grb2's C-terminal SH3 domain.
Solid phase immunoassay was performed as described in experimental procedures
using [His]6-Syn A coated microtiter plates. Binding of GST-Grb2 fusion proteins was
detected by using anti-GST antibody. Absorption 405 nm measures the amount of GSTGrb2 (closed circles), GST-Grb2-C-SH3 (open circles), GST-Grb2-N-SH3 (closed
triangles) or GST (open triangles) bound.
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Discussion
Syntrophins have been suggested to function as adapters, linking cellular
proteins to the DGC (76). It is now clear that this adapter protein binds another adapter,
the SH2/SH3 domain protein Grb2. (96). Syntrophin contains polyproline sequences
that bind Grb2. This binding is Ca2+-independent (Figure 3.5, 3.9, and 3.10). This Ca2+independence is significant since Ca2+-binding by syntrophin results in large syntrophin
oligomers and oligomerization occurs utilizing PH1 sequences (91). Ca2+-binding or
oligomerization could block Grb2 binding but this is apparently not the case.
Binding does not occur with fusion proteins lacking the polyproline sequences
(Figure 3.5 and 3.6). The Grb2-C-SH3 and Grb2-N-SH3 domains bind with similar
affinity (Figure 3.10) and both bind to both of syntrophins polyproline regions (in Syn H
and I, data not shown). The affinities measured here are quite high for SH3 interactions
which typically occur in the 1-10 µM range (99) while here we observed affinities
ranging from 35 nM (for Syn A, Figure 3.10) to 563 nM (for full-length Syn, Figure 3.7).
Thus, syntrophin binding to Grb2 represents one of the highest affinity interactions
known for either protein, which argues strongly for its physiological relevance. Both the
proline-rich sequences at syntrophin 44-75 (present in Syn H) and the one at 181-229
(present in Syn I) bind Grb2 (Figure 3.6 and Figure 3.9). The Kd of Syn H and Syn I are
182 nM and 171 nM, respectively, which are intermediate between that of Syn (563 nM)
and Syn A (35 nM), suggesting that binding to both sequences are required for highest
affinity Grb2 binding. Since Grb2 has two SH3 domains that bind to syntrophin with
similar affinity (Figure 3.10) presumably the two domains of Grb2 bind the two sequence
71

regions of syntrophin. In their study to design peptides which bound with high affinity to
the SH2/SH3 adapter protein Crk, Posern, et al.(99) found that affinities as high as 96
nM (for Crk-N-SH3) or 11 µM (for Grb2-N-SH3) could be achieved with peptides only 11
amino acids long. Sparks, et al.(97) have used 16-long combinatorial libraries to
characterize the PXXP SH3-binding motifs. Thus, 10-16 amino acids should be
sufficient to define the binding sites on syntrophin. There are four PXXP motifs in Syn A,
which fall into two groups: group 1 containing one PXXP motif
EPGAAPPQLPEALLLQ (63-78)
present in Syn H and group 2 containing three PXXP motifs:
VGWASPPASPLQRQPS (179-194)
SPLQRQPSSPGPQPRN (187-202)
VSRRCTPTDPEPRYLE (216-231)
present in Syn I.
Both groups bind Grb2 (Figure 3.6 and Figure 3.9). Some Grb2 interactions, such
as the Grb2-dynamin or Grb2-SOS interaction, are essentially mediated by the single Nterminal SH3 domain of Grb2 (100,101), however, our data strongly suggest that both
SH3 domains of Grb2 bind syntrophin well and both PXXP-regions of syntrophin are
bound by both SH3 domains of Grb2. The interaction is specific for Grb2; muscle Grb2
binds, while muscle Crk-L is not bound. SH3 domains are thus necessary but not
sufficient for this specific interaction. (97,102). As can be seen from Figure 3.9, Grb2
does not bind preferentially to either one of the PXXP regions. The difference in the
binding affinities for the Syn-Grb2 interaction and that of the Syn A-Grb2 interaction is
interesting. The binding affinities for the Syn-Grb2 interaction (563 nM) and that of the
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Syn A-Grb2 interaction (35 nM) differ by an order of magnitude (Figure 3.8) but either
one is still a quite high affinity. This is possible if the polyproline sites that are involved in
Grb2 interaction are less accessible in the full-length syntrophin and by removing the Cterminal part of syntrophin (Syn B), these sites are made more accessible in Syn A.
When the PXXP motifs are separated and are more accessible in Syn H and Syn I, the
apparent dissociation constants are 182 nM and 171 nM, respectively, which are
intermediate between that of Syn (563 nM) and Syn A (35 nM). Both Grb2 SH3 domains
bind to both regions of syntrophin (data not shown) and the affinities are quite similar.
Our model to account for the affinities is that the two motif groups are less accessible in
Syn and become more so in Syn A. The two SH3 domains of Grb2 can bind to each
motif group, resulting in many possible ways to bind the multiple sites and high affinity
binding. When the motifs are separated in Syn I and Syn H, binding is restricted to
simple, single interaction of lower apparent affinity.
Simply mixing the Syn A and Syn B sequences did not reconstitute the lower
affinity suggesting that the intact, covalent structure is required. The binding affinity for
Syn-Grb2 interaction would probably be of more significance to the in vivo situation.
Syntrophins are PH/PDZ domain adapter proteins that bind Na+-channels (60),
NO synthetase (57,58), dystrophin, α- and γ- sarcolglycans (46), SAPK3 (59) and to
themselves (91). This self-association could bring together cellular signaling
components and ion channels. That syntrophin binds the SH2/SH3 adapter protein,
Grb2, brings together a large number of motifs important to cellular signaling in one
place within the cell. SH2/SH3 adapters are necessary for MAP kinase pathway
activation and tyrosine kinase recruitment in many different cell processes. Grb2 has
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also been shown to recruit focal adhesion kinase, FAK125, to the DGC (72,73).
Phosphorylated tyrosines on FAK125 act as docking sites for molecules such as Grb2
that participate in multiple signal transduction pathways (103). The Grb2-SOS complex
also binds to small G proteins such as Ras or Rac1 leading to activation of signaling
pathways to initiate cell growth and differentiation. Thus, the association of Grb2 with
syntrophin (this report) and β–dystroglycan (45) could have important roles in muscle
regulation and growth.
Syntrophin also binds calmodulin (48,53,54) and while Ca2+-calmodulin inhibits
the syntrophin-dystrophin interaction (48) it does not affect syntrophin/Grb2 binding.
Syntrophins are also found associated near the acetylcholine receptor at the
neuromuscular junction (97) and Grb2 is also bound by the tyrosine phosphorylated
acetylcholine receptor δ-subunit (104). Grb2 additionally binds the C-terminus of βdystroglycan (45), through its N-terminal SH3 domain. Grb2 has been reported to be
present in DGC preparations from bovine brain synaptosomes (72). The presence of
Grb2 and syntrophin in the dystrophin glycoprotein complex preparation (72) and our
ability to trap Grb2 (but not Crk) directly from muscle extracts with syntrophinSepharose strongly supports the hypothesis that the interaction between them observed
in vitro also occurs in vivo (72,73). Indeed, the numerous signal transduction proteins
now known to have association with the DGC makes it almost certain that this complex
is involved somehow in cell signaling as we originally suggested in 1992 (53). Within
this complex, the dystroglycan proteins bind the muscle laminin, merosin (105). This
may be the receptor function of the complex, much as the binding of fibronectin and
other RGD sequence proteins initiate integrin signaling. In fact, there is great similarity
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between what is known of the signal transduction proteins associated with the DGC and
what is known of integrin signaling, as has been pointed out by Yoshida, et al. (73). It
may be that signaling cellular attachment to laminin is the long sought function of this
complex.
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Chapter 4. Skeletal Muscle Signaling Pathway Through The
Dystrophin Glycoprotein Complex And Rac 1

Introduction
In skeletal muscles, dystrophin and syntrophins are found in a complex with other
proteins and glycoproteins, the dystrophin glycoprotein complex (DGC1) (6,20) whose
defects cause Duchenne, Becker, various limb girdle, and other inheritable muscular
dystrophies. The integrity of the complex is essential for muscle cell viability (63,106110). The DGC provides a link between laminin in the extracellular matrix and the
cytoskeleton (16,37).
Madhavan and Jarrett originally proposed in 1992 that the DGC was a signal
transduction complex (53). Indeed, the numerous signal transduction proteins now
known to have association with the DGC makes it almost certain that this complex is
involved somehow in cell signaling. β-dystroglycan has been shown to bind to Grb2,
suggesting that it may have a role in signal transduction mechanisms. Grb2 has also
been shown to recruit focal adhesion kinase, FAK125, to the DGC (72,73).
Phosphorylated tyrosines on FAK125 act as docking sites for molecules such as Grb2
that participate in multiple signal transduction pathways.
Syntrophin has been shown to bind neuronal nitric oxide synthetase (56,111)
muscle and nerve voltage gated Na+ channels (60), and the MAP kinase, SAPK3 (59).
Syntrophins also bind calmodulin (53). A domain unique to syntrophins, the SU domain,
has been shown to bind Ca2+-calmodulin (48) and the SU domain in addition to other
sequences in the C-terminal of the protein binds to dystrophin. Ca2+-calmodulin binding
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inhibits the syntrophin-dystrophin interaction (48). The N-terminal of the PH1 domain
and the N-terminal of the PDZ domain have been reported to bind calmodulin (54) in a
Ca2+-independent manner (48,91). This domain has also been shown to be involved in
the oligomerization of syntrophin in vitro in a Ca2+-dependent manner. Calmodulin
inhibits oligomerization in a Ca2+-independent manner (91). Recently, syntrophin has
been shown to bind Grb2, an SH2/SH3 adapter protein (112). Thus, syntrophins act as
adapters between the dystrophin complex of proteins and components of the cell
signaling apparatus.
Cell signaling often involves small G proteins. Adapter proteins such as Grb2
often recruit other proteins, which activate small G proteins. Rho family GTPases, such
as Rac1, Cdc42, and Rho-A, regulate a wide spectrum of cellular functions, ranging
from cell growth and cytoskeletal organization to secretion (113-116). They are critical
for skeletal muscle differentiation and regulate the expression of MyoD and myogenin
(117,118). Ras proteins are central to the control of cell growth and differentiation.
Within the DGC complex, the dystroglycans bind to muscle laminin2, merosin,
the striated muscle isoform of laminin (119,120). We originally proposed that signaling
cellular attachment to laminin might be the long sought function of this complex (112).
We present here for the first time data suggesting that dystrophin glycoprotein complex
is indeed a laminin receptor and through dystroglycans, dystrophin and syntrophin
cause signaling which would promote muscle growth.
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Experimental procedures

Materials
GDP, GTP, and GTP-γ-S were purchased from Sigma. Antibodies against H-Ras,
phosphorylated JNK, Rho-A, and Sos were from Santa Cruz Biotechnology. Antibody
against Rac1 was from Upstate Biotechnology. Antibody against Cdc42 was from
Transduction Laboratories. Antibodies against β−dystroglycan and dystrophin were from
Novocastra. Antibody against recombinant mouse α-syntrophin was produced in rabbit
and purified by affinity chromatography on syntrophin A-Sepharose. Antibody against
α and β−dystroglycan was a generous gift from Dr. Tamara C. Petrucci (Laboratorio di
Biologia Cellulare, Instituto Superiore di Sanita, V. le Regina Elena, Roma, Italy). Goat
anti-mouse IgG (H+L)- horseradish peroxidase conjugate and goat anti-rabbit IgG
(H+L)-horseradish peroxidase conjugate were from BioRad. Ni2+-NTA-agarose was
from Qiagen. Cyanogen bromide pre-activated Sepharose and heparin-Sepharose were
from Sigma. Mouse laminin was obtained from Collaborative Biomedical products. All
other chemicals were of the highest purity available commercially.

Fusion proteins
The syntrophin fusion protein [His]6-Syn was prepared and purified as described
previously (48). GST-Rac1 (wild type), GST-Rac1 (V12), GST-Rac1 (N17) and GSTPAK1 were kindly provided by Dr. Yi Zheng (Department of Molecular Sciences,
University of Tennessee, Memphis). GST-Rac1, GST-Rac1 (V12), GST-Rac1 (N17) and
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GST-PAK1 were expressed in E.coli BL21 strain and purified by affinity chromatography
on glutathione-agarose beads (Amersham Pharmacia Biotech) as described elsewhere
(92,93). The purity of the proteins was determined by 12% SDS-polyacrylamide gel
electrophoresis using the method of Laemmli (78). The major bands of the fusion
proteins were of expected size and relatively high purity (data not shown). The Bradford
assay (79) was used to determine the protein concentrations using bovine serum
albumin as the standard.

Skeletal muscle membrane preparation
3 g of frozen rabbit skeletal muscle (back muscle, predominantly fast twitch
fibers) was homogenized in 7 volumes of pyrophosphate buffer (20 mM sodium
pyrophosphate, 20 mM sodium phosphate, 1 mM MgCl2, 0.303 M sucrose, and 0.5 mM
EDTA, pH 7.0) in the presence of a protease inhibitor cocktail (1 µg/ml pepstatin A, 10
µg/ml leupeptin, 10 µg/ml aprotinin, 1 mM benzamidine, 0.1 mM phenylmethylsulfonyl
fluoride) to minimize protein degradation (92). The homogenate was centrifuged 13,000
x g for 15 min at 40. The supernatant was then centrifuged for 30 min at 32,500 x g at 40
to pellet total muscle membrane. The precipitated total muscle membranes were
suspended in 600 µl of 50 mM Tris, pH 7.5, 100 mM NaCl. 10 µl of muscle membrane
preparation was saved and labeled as crude (Cr).

Preparation of PAK1-glutathione-agarose
A chimeric fusion of glutathione-S-transferase (GST) and the p21-binding domain
of p21 activated kinase (PAK1) was expressed in E. coli BL21 strain. GST-PAK1 and
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GST were then purified by affinity chromatography on glutathione-agarose beads as
described earlier (92,93), the only difference being that after washing the beads
thoroughly the protein was not eluted from the beads.

Solid phase binding assays
0.9 mg of [His]6-Syn (0.9 mg/ml) was coupled to 1 g of cyanogen bromideactivated Sepharose (Sigma) using procedures recommended by the manufacturer
(Pharmacia). The support was then washed with the coupling buffer (0.1 M NaHCO3, pH
8.3, 0.5 M NaCl) and blocked for 2 hr with 0.1 M Tris-HCl, pH 8, 0.5 M NaCl. The
amount of the protein coupled (0.120 mg Syn/ml 50% Sepharose slurry) was
determined by the difference in the ultraviolet absorption of the added protein and that
recovered from coupling in the wash fractions. For negative controls, CNBr-activated
Sepharose was used to which no protein was coupled. Mouse laminin was coupled to
cyanogen bromide-activated Sepharose by following a similar protocol (0.07 mg
laminin/ml 50% Sepharose slurry).

Pull-down assay
100 µl of a 50% slurry of Syn-Sepharose (containing 12 µg Syn) was equilibrated
with buffer K (20 mM Hepes, pH 7.5, 10 mM MgCl2). Rabbit skeletal muscle membranes
were incubated with control Sepharose (Ct), Syn-Sepharose (Syn), laminin-Sepharose
(L), GST-PAK1-glutathione-agarose or GST-glutathione-agarose in buffer K containing
1 mM GTP-γ-S, 1 mM CaCl2 for 1 hr at 40 with gentle mixing and then solubilized by
addition of 2x Dig (50 mM Tris, pH 7.4, 0.5 M NaCl, 0.5 M sucrose, 2% digitonin).
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Incubation was continued for another 1 hr at 40 with gentle mixing. The samples were
centrifuged at room temperature for 5 min at 14000 rpm in a microfuge. The resin was
washed three times with 1 ml of buffer K containing 1% digitonin. The bound protein
was eluted using 60 µl of twice concentrated Laemmli sample buffer (78). Samples were
heated for 5 min at 950 and centrifuged for 5 min at room temperature to remove the
resin. The supernatants were applied to electrophoresis on a 12% SDS-PAGE gel (78),
and electroblotted to nitrocellulose paper (80). The paper was blocked with 10 mg/ml
BSA in TTBS. After washing three times with 1 mg/ml BSA/TTBS, the blot was
incubated with affinity purified anti-Syn (1:3000 dilution), anti-Rac1 (Upstate
Biotechnology, 1:1000 dilution), anti-RhoA (Santa Cruz Biotechnology, 1:50 dilution),
anti H-Ras (Santa Cruz Biotechnology, 1:1000 dilution), anti-Cdc42 (Transduction
Laboratories, 1:500 dilution), or anti-Sos (Santa Cruz Biotechnology, 1:1000 dilution).
Goat anti-rabbit IgG (H+L)-horseradish peroxidase conjugate and goat anti-mouse IgG
(H+L)-horseradish peroxidase conjugate (both 1:1000 dilution) were used for the rabbit
and mouse primary antibodies, respectively. The blots were then developed using the
enhanced chemiluminescence method (112).
For experiments where laminin was removed using heparin-Sepharose, the
skeletal muscle membrane preparation was divided into two portions so that one portion
was twice that of the other (200 and 400 µl each). The larger portion was incubated with
heparin-Sepharose (200 µl of packed heparin-Sepharose) and the smaller portion was
incubated with control-Sepharose (100 µl of packed Sepharose) for 1 hr at 40 with gentle
mixing. The samples were then centrifuged in a microfuge at room temperature at
14000 rpm for 5 min. The supernatants were saved. The supernatant from heparin81

Sepharose was divided into two equal portions (200 µl each). To one part 2 µl of 1
mg/ml exogenous laminin was added. No laminin was added to the other portion. The
rest of the experiment was performed as described above. Removal of laminin was
confirmed by probing the supernatant from heparin-Sepharose with antibody against
merosin (Novocastra, 1:100 dilution). The presence of dystrophin, and dystroglycans in
the supernatant was confirmed by their respective antibodies (data not shown).
For the antibody blockade experiments, skeletal muscle membranes were
divided into two equal portions. To one portion syntrophin antibody (α-Syn) while to the
other portion anti maltose-binding protein antibody (α-MBP) was added as an unrelated
antibody (both antibodies added to a final concentration of 1%) and incubated for 1 hr at
40 with gentle mixing. Then the muscle membrane preparation was incubated with 100
µl of control-Sepharose (Ct) or 100 µl of laminin-Sepharose (L) for 1 hr at 40 with gentle
mixing in buffer K containing 1 mM GTP-γ-S, 1 mM CaCl2 and then for another 1 hr with
1% digitonin. The rest of the experiment was performed as described above.

Phosphorylation of JNK
Laminin was removed from rabbit skeletal muscle microsomes using heparinSepharose as described above. To the laminin depleted portion of the microsomes
either 3 µl of 1 mg/ml exogenous laminin, 1 µM RGDS, or 1 µM RGES peptide was
added in buffer K containing 1 mM GTP-γ-S, 1 mM CaCl2, and 1 mM ATP for 1 hr at 40
with gentle mixing. Microsomes were then solubilized by adding 1% Triton X-100, 0.5%
IGEPAL and 0.5% sodium deoxycholate. Incubation was continued for another 1 hr at
40 with gentle mixing. Microsomes were then “pre-cleared” with Protein G Sepharose
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(25 µl) by incubation for 30 min at 40 and then incubated with 5 µg of anti-βDG antibody.
The immune complexes were then incubated with Protein G-Sepharose for 1 hr,
precipitated and washed extensively with buffer K. The bound proteins were detected by
anti-phosphorylated-JNK antibody (1:1000 dilution) and visualized by ECL.

Results
Two components of the DGC bind Grb2 and recruitment and activation of small
G-proteins is usually a consequence of the action of Grb2. Since the DGC binds laminin
we investigated if laminin binding to the DGC initiates signaling by activating small Gproteins. Laminin-Sepharose (L) or control –Sepharose (Ct) were incubated with rabbit
skeletal muscle membranes. The gel blot of the bound protein was probed with
antibodies against Rac1, Rho-A, Cdc42, and Ras, respectively. Laminin binding to Rac1
is shown in Figure 4.1. It can be seen from the figure that all the G-proteins tested are
present in the rabbit skeletal muscle membrane preparation. Sepharose without any
protein coupled to it was used as a negative control and did not show any binding of Gproteins. Cdc42 did not show any binding to the laminin receptor. Laminin-Sepharose
showed strong binding of Rac1 and to a lesser extent of Rho-A and Ras.
Syntrophin binds Grb2 with high affinity (112) and Grb2 is often involved in
pathways for activating small G proteins. Furthermore, syntrophin self-associates (91)
and thus syntrophin-Sepharose can be used to bind complexes containing syntrophin.
To investigate if syntrophin recruits any of the small G-proteins found in Figure 4.1,
syntrophin-Sepharose (Syn) or control-Sepharose (Ct) were used in a pull-down assay.
Briefly, syntrophin-Sepharose or control-Sepharose were incubated with detrgent
83

Figure 4.1 Rac1 from rabbit skeletal muscle membrane preparation precipitates with
laminin.
Laminin-Sepharose (L) or control-Sepharose (Ct) was incubated with rabbit skeletal
muscle membranes in buffer K containing 1 mM CaCl2, 1 mM GTP-γ-S. After washing,
bound proteins were eluted with SDS-PAGE sample buffer. Samples, after
electrophoresis and electroblotting, were probed with antibodies against Rac1, Rho-A,
Ras, and Cdc42. Cr represents crude extract, Ct represents control-Sepharose that was
used as negative control, and L represents the laminin-Sepharose bound fraction. The
arrows show the expected size of Rac1, Rho-A, Cdc42, and Ras, respectively.
Molecular mass markers are shown to the right.
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solubilized rabbit skeletal muscle membranes and the bound protein fraction was
probed with antibodies against Rac1, Rho-A, Cdc42, and Ras, respectively. Figure 4.2
shows that syntrophin specifically binds to Rac1. None of the other G-proteins tested
showed any appreciable binding, although all four G-proteins are present in the rabbit
skeletal muscle membrane preparation. Control-Sepharose did not show any binding to
any of the proteins tested.
α7β1 integrin is a laminin receptor on skeletal and cardiac muscles (121,122)
and serves as a transmembrane link between basal lamina and muscle fibers.
Laminin10/11 is more active than fibronectin in promoting cell migration and recruitment
of Rac1, via the p130 Cas-Crk II –DOCK 180 complex (123). Therefore the observed
recruitment of Rac1 could be through the laminin -integrin pathway. Heparin has been
shown to inhibit the interaction of laminin with α−dystroglycan (124). Laminin binds
heparin (125). Heparin-Sepharose has been used to purify laminin alpha 1 and alpha 4
chains (126). To prove our hypothesis that dystrophin glycoprotein complex is a laminin
receptor and the recruitment of signaling proteins is in response to laminin binding to
α−dystroglycan and not through the integrins, rabbit skeletal muscle membranes were
incubated with heparin- Sepharose to remove any endogenous laminin. The
supernatant, devoid of laminin (data not shown), was added to control-Sepharose (Ct)
or Syn-Sepharose (Syn). To one set, exogenous laminin was also added. The gel blot
of the bound protein was probed with the Rac1 antibody. It can be seen from Figure 4.3
that Rac1 (arrow on the right side) is recruited only when laminin is present in the
muscle membrane preparation. When laminin was removed by using heparinSepharose, syntrophin did not recruit any detectable amount of Rac1. Rac1
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Figure 4.2 Syntrophin pulls down Rac1 specifically from rabbit skeletal muscle
membranes.
Syntrophin-Sepharose (Syn) or control-Sepharose (Ct) was incubated with the rabbit
skeletal muscle membranes in buffer K containing 1 mM CaCl2, 1 mM GTP-γ-S. After
extensive washing, bound proteins were eluted with SDS-PAGE sample buffer.
Samples, after electrophoresis and electroblotting, were probed with antibodies against
Rac1, Rho-A, Ras, and Cdc42. Cr represents crude extract, Ct represents controlSepharose that was used as negative control, and Syn represents the Syn-Sepharose
bound fraction. The arrows show the expected size of Rac1, Rho-A, Cdc42, and Ras,
respectively. Molecular mass markers are shown to the right.
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Figure 4.3 Rac1 is recruited only when DGC is attached to laminin.
Rabbit skeletal muscle membranes were incubated with heparin-Sepharose for 1 hr at
40. After centrifugation, the supernatant was incubated with Syn-Sepharose (Syn) or
control-Sepharose (Ct) in buffer K containing 1 mM CaCl2, 1 mM GTP-γ-S with or
without addition of exogenous laminin. After extensive washing, bound proteins were
eluted with SDS-PAGE sample buffer. Samples, after electrophoresis and
electroblotting, were probed with antibody against Rac1. Cr represents crude extract, Ct
represents control-Sepharose that was used as negative control, and Syn represents
the syntrophin-Sepharose bound fraction. The arrows show the expected size of Rac1.
Molecular mass markers are shown to the right.
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was recruited by syntrophin when exogenous laminin was added. Muscle membranes
with endogenous laminin were used as a positive control for recruitment of Rac1 by
syntrophin. Rac1 has been shown to undergo oligomerization (127); the band shown
with asterisk in the figure may be the dimeric form of Rac1. Laminin has been used to
isolate DGC proteins (25) and therefore the DGC proteins could be removed by the
heparin-Sepharose treatment. To show this was not the case, the presence of
components of the DGC in the muscle membrane preparation was confirmed by probing
the supernatant of heparin-Sepharose with antibodies against dystrophin, βdystroglycan and α-dystroglycan (data not shown). Thus, heparin-Sepharose effectively
removes laminin while leaving the DGC intact in muscle membranes.
To confirm that syntrophin is involved in the signaling through the DGC, skeletal
muscle membranes were incubated for 1 hr with either syntrophin antibody (α-Syn) or
maltose binding protein antibody (α-MBP, as a negative control) and then with either
laminin-Sepharose (L) or control-Sepharose (Ct). The bound protein was detected with
Rac1 antibody. It can be seen from Figure 4.4 that Rac1 is a part of the complex bound
by laminin in the presence of anti-MBP, which serves as an unrelated antibody. In the
presence of syntrophin antibody, laminin fails to pull-down Rac1 from skeletal muscle
membranes. Thus, addition of syntrophin antibody blocks Rac1 recruitment, strongly
suggesting that Rac1 is recruited to the DGC via syntrophin.
The serine/threonine protein kinases p21Cdc42/Rac-activated kinases (PAKs) are
activated upon binding to the GTP- bound form of Rac1 and Cdc42 (128,129). Since
PAK1 is an effector of Rac1, a GST chimeric fusion with the p21-binding domain (PBD)
of PAK1 on glutathione-agarose, and GST on glutathione-agarose (a negative control),
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Figure 4.4 Rac1 is recruited to the DGC via syntrophin.
Rabbit skeletal muscle membranes were incubated with antibodies against maltose
binding protein (α–MBP) or syntrophin (α-Syn) in buffer K containing 1 mM CaCl2, 1 mM
GTP--γ−S for 1 hr at 40 and then with control-Sepharose (Ct) or laminin-Sepharose (L)
for 1 hr at 40. After extensive washing, bound proteins were eluted with SDS-PAGE
sample buffer. Samples, after electrophoresis and electroblotting, were probed with
antibody against Rac1. Cr represents crude extract, Ct represents control-Sepharose
that was used as negative control, and L represents the laminin-Sepharose bound
fraction. The arrow shows the expected size of Rac1. Molecular mass markers are
shown to the right.
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were incubated with skeletal muscle membranes. The gel blot of the bound protein was
probed with antibodies against syntrophin, β−dystroglycan and Rac1. Figure 4.5 shows
that PAK1 pulled down a complex containing syntrophin (top arrow), β−dystroglycan
(middle arrow), and Rac1 (bottom arrow). The presence of β−dystroglycan and
syntrophin shows that PAK1 is pulling down the DGC along with Rac 1.
Syntrophin, which itself is an adapter protein, has been recently shown to bind
Grb2, an SH2/SH3 adapter protein (112). To identify the guanine nucleotide exchange
factor involved, syntrophin-Sepharose (Syn) or control-Sepharose (Ct) were incubated
with rabbit skeletal muscle membranes and the bound protein fraction was probed with
antibody against son of sevenless, Sos. Figure 4.6 shows that Sos is present in the
skeletal muscle membranes (Cr) and Sos shows strong binding to syntrophin (Syn) and
to a lesser extent to control-Sepharose (Ct).
Sos catalyzes the exchange of GDP to GTP on Ras and Rac (130). In the
activated GTP bound form Ras and Rac activate several downstream kinases such as
JNK/SAPK (131-133). Figure 4.7 shows the effect of laminin binding to the DGC on JNK
activation. The phosphorylation state of JNK in the presence or absence of laminin was
detected using anti-phosphorylated-JNK antibody. JNK2 is activated only when laminin
is present and bound to the DGC while JNK1 is activated when laminin is either absent
(laminin depleted microsomes) or presumably not bound to the complex (in the
presence of heparin). Activation of JNK2 seen by the addition of exogenous laminin to
the microsomes confirms that the observed effect is due to laminin binding to the
dystrophin glycoprotein complex. Heparin interrupts the interaction between laminin and
α-dystroglycan and it can be seen from Figure 4.7 that heparin induces a laminin90

Figure 4.5 Syntrophin recruits p21-activated kinase.
Rabbit skeletal muscle membranes were incubated with GST or GST-PAK1 bound to
glutathione-Sepharose in buffer K containing 1 mM CaCl2, 1 mM GTP-γ-S for 1 hr at 40
and then digitonin was added to the muscle membranes and incubated for 1 hr at 40.
After extensive washing, bound proteins were eluted with SDS-PAGE sample buffer.
Samples, after electrophoresis and electroblotting, were probed with antibodies against
syntrophin (αSyn), β-dystroglycan (βDG), and Rac1 (Rac1). Cr represents crude
extract. The top arrow shows the expected size of syntrophin detected by its antibody
(αSyn), the middle arrow shows the band detected by β -dystroglycan antibody (βDG),
and the bottom arrow shows the band detected by the Rac1 antibody (Rac1). Molecular
mass markers are shown to the right.
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Figure 4.6 Son of sevenless (Sos) is recruited by syntrophin.
Rabbit skeletal muscle membranes were incubated syntrophin-Sepharose (Syn) or
control-Sepharose (Ct) in buffer K containing 1 mM CaCl2, 1 mM GTP-γ-S. After
extensive washing, bound proteins were eluted with SDS-PAGE sample buffer.
Samples, after electrophoresis and electroblotting, were probed with antibody against
Sos. Cr represents crude extract, Ct represents control-Sepharose that was used as
negative control, and Syn represents the syntrophin-Sepharose bound fraction. The
arrow shows the expected size of Sos. Molecular mass markers are shown to the right.

92

Figure 4.7 JNK2 is activated only when DGC is attached to laminin while JNK1 is
activated when interaction of laminin with DGC is interrupted.
Rabbit skeletal muscle membranes were incubated with heparin-Sepharose for 1 hr at
40. After centrifugation, the supernatant was incubated in buffer K containing 1 mM
CaCl2, 1 mM GTP-γ-S, 1 mM ATP with or without addition of exogenous laminin. 1 µM
RGDS or RGES peptide was added to the laminin depleted microsomes. This
incubation was followed by another incubation with anti β-dystroglycan antibody for 1 hr
at 40. The immune complex was precipitated using Protein G Sepharose. After
extensive washing, bound proteins were eluted with SDS-PAGE sample buffer.
Samples, after electrophoresis and electroblotting, were probed with antibody against
phosphorylated JNK. The arrows show the band detected by phosphorylated JNK
antibody. Molecular mass markers are shown to the right.
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depleted state, showing activated JNK1 while JNK2 is not activated at a detectable
level.
Laminin has also been shown to bind α7β1 integrin and therefore to confirm that
the observed activation of JNK is due to laminin binding to the DGC and not to the
integrins, laminin was removed from the microsomes with heparin-Sepharose as
described in the materials and method section. To the laminin depleted microsomes, 1
µM RGDS or 1 µM RGES peptide was added. It can be clearly seen from Figure 4.7
that the addition of either RGDS or RGES peptide has no effect on the phosphorylation
state of JNK. Different experiments with peptide concentrations of 10 µM, 100 µM, 1
mM, and 2 mM were performed and gave similar results (data not shown). Thus, over a
wide range of concentrations, RGDS, an integrin ligand can not mimic the laminininduced signaling found here. Furthermore, the inactive RGES has the same effect as
RGDS. Thus signaling is not by way of a laminin-integrin interaction but rather is DGC
mediated.
To determine if syntrophin binds to Rac1 directly, an Elisa type experiment was
performed where a microtiter plate was coated with syntrophin and overlaid with GSTRac1 (WT), GST-Rac1 (V12) or GST-Rac1 (N17). None of the forms of Rac1 such as
wild type, GDP-bound or GTP bound forms showed any direct association with
syntrophin (data not shown).

Discussion
Cell signaling proteins are associated with the DGC. Syntrophin and Grb2,
PH/PDZ and SH2/SH3 adapter proteins, respectively, are associated with the DGC
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along with other signaling components (112). These adapter proteins bind to other
proteins and frequently recruit different signal transduction components, which control
cell growth and death. In muscular dystrophies, muscle cells die instead of growing,
suggesting defects in these signaling pathways.
Just as integrins bind to fibronectin to initiate cell signaling, in the present study,
we have shown that the DGC binds to laminin and initiates cell signaling; i.e., the DGC
is a laminin receptor and this is a GTPase coupled receptor. A laminin receptor recruits
Rac1, Ras, and Rho-A (Figure 4.1). The DGC laminin-receptor recruits Rac1 (Figure
4.4). Laminin has been shown to bind α-dystroglycan and integrins (121,122,124).
Recently, we have shown that syntrophin binds with very high affinity to Grb2, an
SH2/SH3 adapter protein (112). Grb2 is often associated with son of sevenless, Sos.
Sos has activity as a guanine nucleotide exchange factor (GEF) for Ras and Rac1. Sos
is composed of multiple functional domains including a Dbl homology domain, PH
domain, a Ras Guanine nucleotide exchange factor (GEF) domain, and a C-terminal
proline rich region. This proline rich region is a binding site for the SH3 domain adapter
proteins such as Grb2, Nck, and CrkII, etc. Syntrophin recruits Sos, presumably through
Grb2 (Figure 4.6). The Dbl homology domain of Sos has been reported to also have a
GEF activity for Rac and to stimulate its downstream kinases, JNK/SAPK (134).
Syntrophin recruits Rac1 from skeletal muscle membranes through a Grb2-Sos complex
but not other G proteins (Figure 4.2, Figure 4.3). Thus, at least one of the small G
proteins, Rac1, is associated with the DGC. The interaction between α-dystroglycan
and laminin is inhibited by heparin (124,135). So when laminin is removed from the
skeletal muscle membranes using heparin-Sepharose, syntrophin can no longer
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precipitate Rac1. On the other hand when exogenous laminin is added to the skeletal
muscle membranes, syntrophin again precipitates a complex containing Rac1. Thus,
DGC is associated with Rac1 only when DGC is attached to laminin (Figure 4.3).
Inhibition of recruitment of Rac1 by the syntrophin antibody strongly suggests that Rac1
is being recruited to the complex via syntrophin (Figure 4.4). p21-activated kinase
(PAK1) is found to be activated upon binding to the GTP-bound forms of Rac1 and
Cdc42 (136,137). PAK1 is implicated in mediating signaling from Rac1 and Cdc42 to
the c-Jun N terminal kinase (138,139), and in certain cases, to the actin cytoskeleton
(140). PAK1 being recruited by syntrophin has been shown in the reverse pull-down
experiment where PAK1-glutathione-agarose was used to pull-down syntrophin along
with β-dystroglycan (Figure 4.5). In addition, PAK1 is being recruited by syntrophin via
Rac1 (Figure 4.5) but not Cdc42 (Figure 4.2).
The role of Rho family proteins (including Rho A, Rac1, and Cdc42) in the
activation of SAPK/JNK has been demonstrated independently by Coso et al. (132) and
Minden et al. (133). Activation of the Rho family G proteins often leads to activation of
Jun N terminal kinases that leads to phosphorylation of c-jun. The stress activated
protein kinases (SAPK) are directly involved in phosphorylation of c-jun. Though often
these Jun N terminal kinases are SAPK1 and SAPK2, this function is also shared by
SAPK3 (141). SAPK3 is associated with syntrophin (59). JNK2 is phosphorylated only
when laminin is attached to the DGC while JNK1 is phosphorylated when the interaction
of laminin with the DGC is interrupted (Figure 4.7). Addition of 1 µM-2 mM RGDS or
RGES peptide shows no effect on the phosphorylation state of JNK1 or JNK2 in the
absence of laminin (Figure 4.7 and data not shown), thus confirming our hypothesis that
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the observed signaling is due to laminin binding to α-dystroglycan and not because of
laminin binding to integrins. Kolodziejczyk et al. (142) have shown that murine models
of DMD display a muscle-specific activation of JNK1. They also reported that
independent activation of JNK1 resulted in defects in myotube viability and integrity in
vitro, similar to a dystrophic phenotype. In addition, direct muscle injection of an
adenoviral construct containing the JNK1 inhibitory protein, JIP1, dramatically
attenuated the progression of dystrophic myofiber destruction. Taken together, these
results suggest that a JNK1-mediated signal cascade could contribute to the
progression of the disease pathogenesis.
We show that the dystrophin glycoprotein complex is a laminin receptor which
signals and propose the effect of signaling is to cause the cell to grow normally
whenever it is attached to merosin (muscle laminin). This signaling pathway is depicted
in Figure 4.8. Merosin (muscle laminin) binds to α-dystroglycan (61), which then signals
through β−dystroglycan, dystrophin and syntrophin. Syntrophin in turn binds to Grb2, an
SH2/SH3 adapter protein. Syntrophin thus bridges the dystrophin glycoprotein complex,
a laminin receptor, to the other proteins namely Grb2 and Sos, which activates the small
G protein Rac1. The GTP-bound form of Rac1 in turn activates p21-activated kinase.
PAK1 then probably leads to subsequent activation of currently unidentified component
of a MAP kinase pathway. The phosphorylation and activation of Jun N-terminal kinase2
may lead to subsequent phosphorylation of c-jun and as a result would regulate AP1
mediated transcription. Phosphorylation of c-jun prevents apoptosis and premature cell
senescence (143). Thus, we propose that the dystrophin glycoprotein complex, by
acting as a laminin receptor, signals the normal muscle cell to grow.
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Figure 4.8 Diagrammatic representation of the signaling pathway.
Laminin by binding to α−dystroglycan (α-DG) through dystrophin glycoprotein complex
recruits Rac1 through Grb2-Sos complex and may signal the normal muscle cell to
grow. The components of the DGC are shown in light gray color, the interactions that
are shown to occur in this report are shown in dark gray color while the proposed but
currently unidentified interactions are shown in white color. The abbreviations for the
DGC proteins are given in the paranthesis. Dystrophin (Dys), α-sarcoglycan (α-SG), βdystroglycan (β-DG), and γ-dystroglycan (γ-SG), β-Sarcoglycan (β-SG), δ-sarcoglycan
(δ-SG) and sarcospan (SP), syntrophin (Syn).
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It has also been reported that agrin, a major component of the basal lamina of
the neuromuscular junction leads to muscle-specific activation of Rac and Cdc42 in
differentiated myotubes and this activation is essential for AchR clustering at synaptic
sites (144). In our lab, we have found that after tenotomy the muscle is no longer
subjected to normal stretching and the DGC receptor down-regulates. In addition to the
down-regulation of the DGC, there is a large effect on G protein signaling through Ras,
Rho-A, and Cdc42 while having very little or no effect on Rac1 signaling (145). Since
atrophied muscle has the potential to rapidly recover from atrophy, it must maintain all
of the components necessary for the recovery. These results also support the
importance of Rac1 signaling.
We have proposed earlier that the DGC may function as a stretch receptor (145).
The signal transduction mechanism for this stretch receptor is not known. However,
stretch signaling of an elastin-laminin receptor involves Grb2 and small GTPase in
smooth muscles (146). In bladder smooth muscles, SAPK2 and JNK are activated as a
result of stretch (147), a frequent consequence of Grb2 and small GTPase signaling.
Thus, our model that the DGC-laminin receptor promotes muscle growth and its putative
function as a stretch receptor regulating atrophy/hypertrophy are similar concepts. In
such a stretch receptor paradigm, laminin would remain attached to its DGC receptor
but would be stressed by stretching.
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Chapter 5. Conclusions

Duchenne and Becker muscular dystrophies are tragic diseases that leave the
victim without much hope for cure. Understanding the molecular basis of these diseases
in order to develop effective treatments for afflicted individuals has been of highest
priority to both scientists and clinicians. A major breakthrough was made about 15 years
ago when the genetic locus causing these myopathies was identified (8).
When we began our studies on syntrophin, nearly 4 years ago, syntrophin was
shown to bind calmodulin (53), PtdIns4,5P2 (52), nNOS (56), Ca2+ (48), SAPK3 (59),
voltage gated sodium channels (60), etc. While the function of syntrophin, and the DGC,
in muscle is unknown, DGC was proposed to play a role as a signal transduction
complex (53), and syntrophin was proposed to function as a modular adapter in
recruiting signaling proteins to the DGC and the membrane (44).
Work in our laboratory has focussed on syntrophin interactions with the cell
signaling proteins and the role of DGC in skeletal muscle. We have shown in this study
that syntrophin undergoes oligomerization in a Ca2+-dependent manner and calmodulin
inhibits it. Ca2+ chelators such as EGTA inhibit oligomerization. Calmodulin is present in
many tissues as high as micromolar and is probably in sufficient concentration to inhibit
or limit the oligomerization of syntrophin.
The presence of a high concentration of solute ions frequently alters the solubility
of proteins and other macromolecules: (i) it causes aggregation or structural collapse of
proteins because of enhancement of hydrophobic interactions; (ii) it interferes with
essential electrostatic interactions within or between molecules because of charge
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shielding. However, syntrophin oligomerization is caused by Ca2+ and not because of
bulk ionic strength. In the case of syntrophin, 1 µM free Ca2+ was added to the buffer
containing 50 mM Tris, pH 7.5, 100 mM NaCl. Addition of 1 µM free Ca2+ would not
change the ionic strength of the buffer significantly. In addition, syntrophin did not show
any precipitation in absence of Ca2+ (at virtually the same ionic strength).
Aggregates form as a result of the nonspecific interaction between partially
folded intermediates or denatured protein. Aggregation occurs in a continuum and
aggregates of virtually any size can occur. The hydrophobic nature of the partially folded
intermediates is believed to be responsible for self-association and thus the formation of
aggregates. While oligomerization is a more structured process caused by the
association of properly folded proteins, in specific stiochiometry and specific domains.
The observed effect was due to oligomerization and not aggregation because i)
specific sequences in and adjacent to the PH1 domain were involved ii) this
oligomerization was inhibited by a specific Ca2+ binding protein, calmodulin. iii) In
addition, in the size exclusion chromatography experiment, several distinct peaks were
observed indicating oligomeric species occur in certain stoichiometries more abundantly
than others. If the observed phenomenon was aggregation then we would have
observed a continuum in one peak instead of several distinct peaks. The syntrophin
oligomerization is also similar to that of actin (84) and tubulin (85) in that Ca2+ is a
regulator and oligomer stoichiometry is affected by regulatory proteins.
In the resting muscle, Ca2+ would be submicromolar in concentration and this
would also limit oligomerization. The calmodulin bound would be the Ca2+-free,
apocalmodulin conformer (55) and our results suggest that each syntrophin would retain
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a calmodulin, increasing the local calmodulin concentration even further. As intracellular
Ca2+ increases, preceding and during muscle contraction, this Ca2+ could bind to
syntrophin and favor syntrophin self-association. Additionally, as Ca2+ binds calmodulin,
calmodulin would be able to bind to other more numerous cell proteins, which bind only
the Ca2+-calmodulin conformer. Thus, Ca2+-calmodulin could be bound elsewhere,
allowing syntrophin's oligomerization. Thus, one can envision syntrophin as monomeric
or simple oligomer (e.g. dimer, etc) in the resting cell and oligomeric in the contracting
muscle. In support of this view, syntrophin is present in 2:1 molar ratio to dystrophin and
other DGC components when isolated in the absence of Ca2+ (19). The oligomeric state
of syntrophin may be important to maintaining the clusters of ion channels at the
neuromuscular junction during contraction (60) and the distribution of calmodulin within
the myofibril (55). Alternatively, syntrophins may respond to Ca2+ during contraction in a
way that makes the protein complexes which contain it more tightly (or loosely)
associated.
Syntrophins are PH/PDZ domain adapter proteins that bind Na+-channels (60),
NO synthetase (56), dystrophin, α- and γ- sarcolglycans (46), SAPK3 (59) and to
themselves (91 and chapter 2). This self-association could bring together cellular
signaling components and ion channels. It is now clear that this adapter protein binds
another adapter, the SH2/SH3 domain protein Grb2 (112 and chapter 3). Syntrophin
contains polyproline sequences that bind Grb2. This binding is Ca2+-independent. This
Ca2+-independence is significant since Ca2+-binding by syntrophin results in large
syntrophin oligomers and oligomerization occurs utilizing PH1 sequences (91).
Syntrophin binds the SH2/SH3 adapter protein, Grb2, and may bring together a large
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number of motifs important to cellular signaling in one place within the cell. SH2/SH3
adapters are necessary for MAP kinase pathway activation and tyrosine kinase
recruitment in many different cell processes. The Grb2-SOS complex also binds to
small G proteins such as Ras and Rac1 leading to activation of signaling pathways
which could potentially initiate cell growth and differentiation.
Just as integrins bind to fibronectin to initiate cell signaling, in this study, we have
shown that the DGC binds to laminin and initiates cell signaling; i.e., the DGC is a
laminin receptor and this is a GTPase coupled receptor. A laminin receptor recruits
Rac1, Ras, and Rho-A. The DGC laminin-receptor recruits Rac1. Rac1 is recruited to
the complex via syntrophin. Activation of the Rho family G proteins often leads to
activation of Jun N terminal kinases (JNK) that leads to phosphorylation of c-Jun. JNK2
is phosphorylated only when laminin is attached to the DGC while JNK1 is
phosphorylated when the interaction of laminin with the DGC is interrupted.
We have shown that the dystrophin glycoprotein complex is a laminin receptor
which signals and propose the effect of signaling is to cause the cell to grow normally
whenever it is attached to merosin (muscle laminin).
Biochemical characterization of DGC proteins is important not only for a
molecular understanding of the cellular protein complex, but also for developing
potential therapeutic and diagnostic techniques. Cox et al. (148) have shown that the
dystrophin gene when expressed in dystrophic tissue can reverse myopathic symptoms.
Kolodziejczyk et al. (142) have shown that murine models of DMD display a musclespecific activation of JNK1. They also reported that independent activation of JNK1
resulted in defects in myotube viability and integrity in vitro, similar to a dystrophic
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phenotype. In addition, direct muscle injection of an adenoviral construct containing the
JNK1 inhibitory protein, JIP1, dramatically attenuated the progression of dystrophic
myofiber destruction. Taken together, these results suggest that a JNK1-mediated
signal cascade could contribute to the progression of the disease pathogenesis. These
studies describe the syntrophin at the sarcolemma and its interactions with other
proteins and help us understand the role played by this complex. Signaling pathways
such as the one we have helped elucidate provide numerous targets for
pharmacological intervention, which may lead to ways to attenuate or alleviate the
destructive course of muscular dystrophies.
A cure for DMD and BMD will have to await a more complete understanding of all
the functions of the DGC proteins and the complex as a whole. Our studies describe
certain important functions of syntrophin, signaling through the DGC, and along with the
pioneering work of several other investigators, attempt to characterize the function and
role of this complex in muscle. The role of the DGC is emerging from these studies and
understanding is tantalizingly close but still elusive.
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